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ABSTRACT  
 Synchronization of follicular wave emergence forms the basis of many 
reproductive management techniques used in the cattle industry such as estrus 
synchronization, fixed-time artificial insemination and embryo transfer. Estrogen in 
combination with progesterone has been used widely for this purpose due to ease of use 
and efficient, consistent and quick results, irrespective of the status of the dominant 
follicle or corpus luteum when the treatment is applied. The recent ban by the European 
Union on use of estrogens in food-producing animals prompted us to examine if 
testosterone could be used as an alternative drug for follicular wave synchronization. We 
tested the hypothesis that the administration of testosterone will shorten the life-span of 
the extant dominant follicle resulting in early emergence of a new follicular wave.  	   We tested two forms of testosterone (conjugated form: testosterone enanthate and 
unconjugated form: non-esterified free testosterone) and determined that intramuscular 
injection of oil-based preparation of the unconjugated form caused a sharp rise in plasma 
concentrations of testosterone followed by a less rapid decline. The pharmacokinetics of 
testosterone in blood plasma of 16 heifers was determined after two intramuscular 
injections of 200 mg of unconjugated testosterone (in 4 ml canola oil) at 12 hour 
intervals. Testosterone C max was 13.9 ng/mL and the distribution half-life of testosterone 
in the bloodstream was 3.2 days. Plasma testosterone concentrations were elevated within 
2 hours, maintained for initial 36 hours and declined to baseline over 13 days.  
 To study the ovarian and endocrine effects of testosterone, heifers (n=6 per group) 
were given two intramuscular injections of 200 mg of unconjugated testosterone in 4 mL 
canola oil at 12 hour intervals on Days 1 (T1), 3 (T3) or 6 (T6) of the first follicular wave 
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(Day 0 = ovulation); the Control group was given 4 mL canola oil. Ovarian structures 
were monitored daily by transrectal ultrasonography over one interovulatory interval and 
plasma samples were collected. Following treatment, the dominant follicle grew more 
slowly for the next 5 days in T1 (P=0.05) and T3 (P=0.06) groups compared to the 
Control group, while the dominant follicle in the T6 group regressed more slowly 
(P=0.02) than in the Control group. The diameter profile of the dominant follicle of the 
post-treatment wave (Wave 2) and the ovulatory wave did not differ between treatment 
and Control groups. Overall, testosterone treatment (T1, T3 and T6 combined) extended 
the duration of current (Wave 1; P=<0.001) wave in 8 out of 17 heifers compared with 
the Control group and emergence of the post-treatment wave was not synchronized. 
Although the interovulatory interval was not affected by the treatments, the proportion of 
2-wave cycles tended to be higher (P=0.08) after treatment (T1, T3 and T6 combined) 
compared to the Control group. The plasma LH concentrations in T1 and T3 groups 
decreased after treatment, while it did not change in T6 group compared to Control 
group. FSH concentrations were not affected by the testosterone treatment. 
 In conclusion, our hypothesis that exogenous testosterone treatment will hasten 
the emergence of next follicular wave, was not supported. Furthermore, testosterone 
treatment did not cause the demise of the dominant follicle. Testosterone treatment 
resulted in slower growth of the dominant follicle when treatment was initiated at or 
before the time of dominant follicle selection, and slower regression of the dominant 
follicle when treatment was initiated during the static phase. These changes appear to be 
mediated by the decline in systemic concentration of LH. In addition, testosterone 
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treatment delayed the emergence of the next follicular wave irrespective of the status of 
the dominant follicle at the time of treatment. 
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1.0 GENERAL INTROUDUCTION  
Basic studies in ovarian function and endocrine control mechanisms have helped 
researchers to develop many reproductive techniques that improve the reproductive 
efficiency of farm animals (Adams, 2007; Mapletoft et al., 2009). Two examples of 
control of ovarian function in cattle are the synchronization of follicle wave emergence 
and synchronization of ovulation. These techniques are applied widely in the cattle 
industry for fixed-time artificial insemination and embryo transfer (Martínez et al., 2004). 
Physical and hormonal methods are available for synchronization of follicular wave 
emergence: dominant follicle ablation, GnRH or LH, and estradiol alone or in 
combination with progesterone (Martínez et al., 2004). Estrogen in combination with 
progesterone has been used widely in the synchronization of follicular waves due to ease 
of use and efficient, consistent and quick results irrespective of the status of the dominant 
follicle or corpus luteum when the treatment is applied (Bo et al., 1995b; Bridges et al., 
1999). In this procedure, the dominant follicle regresses as a result of systemic effect 
(feedback) of progesterone and estradiol on the pituitary gland leading to suppression of 
LH and FSH secretion (Bo et al., 2000). When the suppressive effect of estradiol on FSH 
decreases, a surge of FSH occurs resulting in emergence of new follicular wave (Adams 
et al., 1992a). 
  For decades, estradiol and its analogs have been used as implants to improve the 
feed efficiency and growth rate of beef cattle (Lee et al., 1990; Preston, 1999). Over the 
last 30 years, there has been an ongoing debate about the use of growth promoters in 
cattle due to human health concerns from the residue of hormones in meat or milk 
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(Andersson and Skakkebaek, 1999). As a result, many countries including those in the 
European Union and New Zealand, have banned the use of estradiol in cattle (EC,1996). 
Testosterone is a steroid hormone that is produced locally by theca cells in the 
ovary. Testosterone has an important role in follicular development as a substrate for 
estradiol synthesis and can increase the activity of aromatase in granulosa cells in vitro 
(Wu et al., 2011). Therefore, testosterone may be an alternative to estradiol for use in 
synchronization of follicular waves. Clinicians and researchers have used testosterone in 
farm animals for other purposes, e.g., to androgenize cows for use in detecting estrus 
(Nix et al., 1998). In pigs, testosterone was used during the follicular phase in 
postpubertal gilts to increase the ovulation rate (Cardenas and Pope, 2002). One study 
tested the effect of testosterone in heifers during the follicular phase and found that the 
treatment induced atresia for ovulatory follicles (Rajamahendran and Manikkam, 1994). 
In addition, testosterone treatment has been shown to exert negative feedback on 
gonadotrophins leading to suppression of LH secretion in cows and mares (Thompson et 
al., 1984). The atretogenic effects of testosterone on follicles have been documented in 
rodents by in vivo and in vitro methods and most of these studies point to a negative 
impact of testosterone on granulosa cells (Billig et al., 1993; Daniel and Armstrong, 
1986) resuliting in a reduction in ovarian weight (Hillier and Ross, 1979 ).  
Based on the above cited studies, it is reasonable to propose that exogenous 
testosterone may increase estradiol concentrations by providing readily available 
substrate for aromatization, and by increasing the aromatase activity which in turn could 
exert a negative feedback on the hypothalamic-pituitary axis (Gross, 1980; Roos et al., 
1980; Toranzo et al., 1989) leading to suppression of gonadotrophin hormone release (LH 
	   3	  
and FSH). In addition, testosterone itself has an additive and direct suppressive effect on 
circulating levels of gonadotrophin via negative feedback on the hypothalamus or 
pituitary glands (Gross, 1980; Handa et al., 1986; Roselli et al., 1990). As described 
earlier, increasing estradiol or testosterone will reduce LH pulse amplitude and suppress 
FSH release (Jorgensen and Nilson, 2001; Martínez et al., 2004). These effects may cause 
the dominant follicle to regress and result in emergence of a new follicular wave due to a 
subsequent increase in circulating FSH (as a result of removal of suppressive effect of 
dominant follicle on FSH and subsequent metabolism of estradiol). The main focus of 
this thesis is to examine the effects of testosterone on follicular dynamics and endocrine 
parameters in beef cattle, and to evaluate the feasibility of testosterone as an alternative to 
estradiol for follicular wave synchronization. The review of literature is divided into three 
main sections: physiology and dynamics of follicle development in cattle, methods to 
control the emergence of follicular waves, and effects of testosterone on follicle 
development. 
 
1.1 Physiology of follicular development in cattle  
1.1.1 Ovarian follicles 
 The follicle is a basic unit in the ovary that maintains, nurtures and releases the 
oocyte as well as performs a series of endocrine and paracrine functions during its 
development (produces steroid and non-steroid hormones). Ovarian follicles can be 
classified based on their degree of development from primordial, primary, secondary, 
tertiary to preovulatory follicles (Van den Hurk, 2005). Primordial follicles are 
characterized by a single layer of squamous pre-granulosa cells that surround the oocyte. 
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These are present throughout the reproductive life of the cow and are considered a source 
for other types of follicles (Fortune, 2003). When squamous cells begin to develop in 
cuboidal cells (granulosa cells), the follicle becomes a primary follicle. At this stage, the 
initiation (activation) of follicular growth starts and the granulosa cells begin to divide 
(Braw-Tal and Yossefi, 1997). When the oocyte is surrounded by 2-6 layers of granulosa 
cells, the follicle is called a secondary follicle. Meanwhile, intercellular cavities appear in 
between the dividing granulosa cells and these are filled with fluid. This structure is 
called a follicular antrum (Van den Hurk, 2005) and the follicle is termed as a tertiary or 
antral follicle (Braw-Tal and Yossefi, 1997; Lussier et al., 1987). There are different 
development stages of antral follicles that end in a fully grown follicle (Graafiian or 
preovulatory follicle) of around 15 mm in the cow (Fortune, 1994). The duration of 
follicular development from activated primordial follicle to the preovulatory follicle is 
around 80 to 100 days in cattle (Britt, 1991). 
 
1.1.2 Follicular dynamics in cattle  
 In 1960, Rajakoski was the first researcher who indicated that the growth of 
follicles in cattle occurs in a wave-like manner (Rajakoski, 1960). By using real-time, 
transrectal ultrasonography for ovarian examinations over days, many important events 
have been recognized in follicular growth in cattle and other domestic animals and the 
existence of follicular wave pattern was confirmed (Ginther et al., 1989a; Pierson and 
Ginther, 1987a; Pierson and Ginther, 1987b; Pierson and Ginther, 1984). In cattle, the 
estrous cycle consists of two or three follicular waves (Ginther et al., 1989a; Ginther et 
al., 1989b) and it is still not clear why this variation in number of waves occurs in cattle 
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(Jaiswal, 2004). Follicular waves exist during different physiological conditions such as 
the prepuberal period (Adams et al., 1994; Evans et al., 1994), pregnancy (Ginther et al., 
1996b; Savio et al., 1990a), and postpartum period (Savio et al., 1990a; Savio et al., 
1990b) in cattle. In 2-wave cycles, a follicular waves emerge on Day 0 (day of ovulation) 
and Day 10, on average, while in 3-wave cycles, wave emergence occurs on Days 0, 9 
and 16 (Ginther et al., 1989b). In this regard, the interovulatory interval (that is, the 
duration between two sequential ovulations) is shorter (P<0.01) for 2-wave cycles 
(19.0±0.20 days) than 3-wave cycles (22.5 ±0.30; Jaiswal et al., 2009).  
  At the beginning of every wave, a group of small antral follicles (average, 24 
follicles), detectable by ultrasonography at a diameter of 3-4 mm, grows synchronously 
(Adams, 1999). This group of follicles continues growing for 2-3 days when a single 
dominant follicle (diameter around 8 mm) keeps growing while the others regress 
(subordinate follicles) in a process called selection (Adams et al., 1993a; Ginther et al., 
2000). After selection, an active dominant follicle produces more estradiol that exerts a 
negative feed back on FSH (review, Fortune, 1994; Mapletoft et al., 2002). As a result, 
the reduction in plasma FSH will prevent the growth of subordinate follicles and the 
emergence of a new follicular wave to accrue; this process is called dominance (Adams, 
1999; Ireland et al., 2000).  
 When a dominant follicle grows during the luteal phase, it eventually undergoes 
atresia due to suppression of LH by progesterone produced from the corpus luteum (CL, 
Adams, 1999). However, the dominant follicle that grows during luteolysis will ovulate 
because the decreasing progesterone concentration allows LH to increase and support the 
dominant follicle growth (no suppressive effect; Adams et al., 1992b). The anovulatory 
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dominant follicle and all subordinate follicles go through three development phases. The 
growing phase is the stage during which the follicle grows linearly starting from the first 
detection to the day when the diameter of follicle stop to increase. In the second stage 
(static phase), the follicle keeps differentiating without any change in the diameter. When 
the follicle enters the regressing phase, its diameter begins to decrease until the follicle 
disappears (Ginther et al., 1989b). 
 
1.1.3 Hormonal regulation of follicular development 
  The development and maturation of follicles in late growing phase occurs 
under the influence of growth factors and hormones produced from the hypothalamic-
pituitary-ovarian axis (HPO axis). These hormones include hypothalamic gonadotrophin-
releasing hormone (GnRH) that acts on the anterior pituitary gland to release follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) (Roche et al., 1997). In the 
ovaries, follicles produce estradiol and inhibin, whereas the CL secretes progesterone. 
The uterus secretes prostaglandin F2α (PGF) to control the life-span of the CL (Rathbone 
et al., 2001). Growth factors such as BMP-7, IGF-I and II, TGFβ (Transforming growth 
factor β), and basic fibroblast growth factor (bFGF) play important roles during different 
stages of follicle development (Webb et al, 2004; Ginther et al. 2001b; Skinner, 2005). In 
preantral follicles, TGF? and IGF family growth factors are involved directly in 
activation of follicles while in antral follicles, IGF-I and IGF-II support the growth and 
maturation of follicles (Webb et al, 2004). 
 Many studies have been done to understand the pattern of reproductive 
hormone secretion during the estrous cycle (Fig1.1). In the following section, these 
hormones are discussed in detail with reference to folliculogenesis.  
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Fig.1.1 Temporal associations between the follicular wave emergence, dominant follicle 
diameter, corpus luteum diameter, ovulation (Fig A) and plasma concentrations of 
gonadotropins and steroid hormones (Fig. B) during a 2-wave estrous cycle in cattle. 
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1.1.3.1 Gonadotrophin-releasing hormone (GnRH)  
 GnRH is a decapeptide that is synthesized in the cell bodies of neurosecretory 
neurons of the hypothalamus and modulates gonadotroph activity in the anterior pituitary 
to secrete FSH and LH (reviwed at Jadav et al., 2010). The GnRH secretion occurs in a 
pulsatile manner, which results in secretion of LH and FSH in pulses, although only LH 
pulses tightly follow each and every GnRH pulse (Kaiser, 1997; Vizcarra et al., 1997). 
Ovarian steroids, estradiol and progesterone, regulate GnRH through feedback 
mechanisms depending on stage of the estrous cycle (Herbison, 1998; Jadav et al., 2010). 
Progesterone decreases GnRH pulsatility during the luteal phase (Price and Webb, 1988; 
Savio et al., 1993), while estradiol increases GnRH pulses during the follicular phase 
(Karsch and Evans, 1996). A surge in estradiol during estrus also causes surge in GnRH 
which eventually results in LH surge (Kesner et al., 1981; Martinez et al., 2007 
 
1.1.3.2 Gonadotrophin hormones (FSH, LH) 
  Both LH and FSH are glycoproteins consisting of two polypeptide subunits, 
alpha and beta (Baenziger and Green, 1988). The alpha units in both hormones are 
common, but the beta subunit is different and determines the functionality of 
gonadotrophin (Norman and Litwack, 1997; Talmadge et al., 1983). The FSH receptors 
are exclusively present on the granulosa cells of follicles while LH receptors are present 
on both theca cells and granulosa cells (Xu et al., 1995; Bao and Garverick, 1998) as well 
as in luteal cells (Niswender,1981). The growth of preantral follicles is gonadotrophin 
independent and is believed to be regulated by growth factors (Wandji et al., 1996). In 
early stages of follicle development, the growth factors that are produced from oocytes 
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and granulosa cells play important roles in initiation of follicles growth (Wandji et al., 
1992; Fortune et al., 2000). Some in vitro and in vivo studies suggested that FSH can 
increase the rate of preantral follicle development (Campbell et al., 2000; Hulshof et al., 
1995). Antral follicles at early stages need FSH, for growth (Adams et al., 2008; Jaiswal 
et al., 2004). An increase in FSH is followed by appearance of 3-4 mm follicles 
(follicular wave emergence) a day later (Adams et al., 1992b; Jaiswal et al., 2004). Mean 
FSH concentrations increase 6-8 h before wave emergence and remain elevated for 8 h 
after wave emergence (Ginther et al., 1998; Jaiswal et al., 2004). Follicles, growing under 
the FSH support, start producing more estradiol and inhibin which act on the anterior 
pituitary to inhibit FSH secretion through a negative feedback mechanism (Gibbons et al., 
1997). The decline in FSH concentration is closely related with the selection of one 
follicle as dominant and others as its subordinates (Adams et al., 1992a; 1993a; 1999). 
During this period, the number of LH receptors on granulosa cells increases (2-4 day after 
wave emergence), indicating the role of LH in dominant follicle selection (Campbell et 
al., 1995; Ginther et al., 2001a). After selection, the dominant follicle is dependent on LH 
for growth; suppression of pulsatile secretion of LH with a GnRH agonist prevented the 
dominant follicles from growing beyond 7-9 mm (Gong et al., 1996). On the contrary, 
subordinate follicles undergo atresia due to lack of FSH availability and LH receptors 
(Ginther et al., 2001a; Ginther et al., 2001b). Progesterone inhibits LH pulsatility, this 
results in the regression of the dominant follicle during anovulatory waves (Savio et al., 
1993). The loss of dominance also results in a decrease in estradiol thus overcoming the 
negative feedback on FSH secretion from pituitary (Ginther et al., 2003). As a result, 
FSH concentration rises again and a new follicular wave emerges (Rathbone et al., 2001). 
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When progesterone concentration declines with the demise of the CL, the dominant 
follicle continues to grow to produce peak estradiol concentrations which cause an LH 
surge allowing the dominant follicle to ovulate (Rathbone et al., 2001). Pulsatility of LH 
also regulates progesterone production from lueal cells and was shown to have an 
essential role in maintenance of CL function (Niswender, 2000). 
 
1.1.3.3 Ovarian hormones (estradiol, progesterone)  
  Progesterone and estradiol are steroid hormones derived from cholesterol. 
Within the follicle, cholesterol is converted to progesterone under influence of LH by 
stimulating steroidogenic acute regulatory protein (StAR) enzyme in theca and granulosa 
cells. Progesterone converts to testosterone in the theca cells, the latter is transported to 
granulosa cells for conversion to estradiol (Norman and Litwack, 1997). Figure 1.1 
illustrates the key enzymes required for biosysnthesis of estradiol by the follicular wall. 
The primary source of circulating concentrations of progesterone is the CL, while that of 
estradiol is from ovarian follicles. Systemic concentrations of progesterone plays an 
important role in regulation of LH secretion by exerting negative feedback on 
hypothalamus-pituitary axis thereby reducing the concentration of GnRH and LH 
(reviewed in Adams et al., 1992b; Stock & Fortune, 1993; Mihm et al., 2002).  
 During mid-cycle, high concentrations of progesterone reduce LH pulse 
frequency and result in regression of the unovulatory follicle (Adams et al., 1992b; 
Adams, 1999; Savio et al., 1993). During luteolysis, progesterone concentrations 
decrease, thus removing the suppression on LH pulse frequency and allowing the 
dominant follicle to grow and the preovulatory surge of LH to accrue (Savio et al., 1993). 
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A differential effect on LH and FSH is seen during mid-cycle. While FSH increases 
periodically during high circulating levels of progesterone to induce new wave 
emergence (Adams et al., 1992b), LH does not increase when the progesterone 
concentration is high (Mihm et al., 2002). 
 Estradiol is synthesized in granulosa cells by aromatization of testosterone 
and is involved in regulation of gonadotrophin hormones by exerting negative and 
positive feedback on hypothalamus–pituitary axis (Youngquist and Threlfall, 2007). 
Estradiol modulates neurotransmitters in hypothalamus that control GnRH pulsatile 
secretion (reviewed in Smith and Jennes, 2001) and increases the responsiveness of the 
anterior pituitary gland to GnRH by elevating the density of GnRH receptors 
(Schoenemann et al., 1985). During the estrous cycle, changes in estradiol concentrations 
regulate the timing of wave emergence and ovulation through its effect on gonadotrophin 
hormones (Fortune, 1994; Mihm et al., 2002). Many studies have documented the role of 
estradiol in dominant follicle selection by suppressing FSH concentration to prevent 
smaller (subordinate) follicles to grow or a new wave to emerge (Adams and Pierson, 
1995; Ginther et al., 1998; Ginther et al., 2000). When progesterone concentrations 
decline during proestrous, estradiol increases sufficiently to stimulate the hypothalamus 
to increase the frequency and amplitude of GnRH pulses (Hansel and Echternkamp, 
1972). Consequently, LH frequency and amplitude are increased to stimulate follicular 
maturation and finally results in the LH peak which causes ovulation (Walters and 
Schallenberger, 1984).  
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Fig. 1.2 Pathway of estradiol synthesis in ovarian follicles of mammals. Testosterone is 
the substrate for estradiol that is produced in the theca cell from cholesterol and from 
progesterone produced in granulosa cells, after a chain of enzymatic reactions. Granulosa 
cells lack 17α-hydroxylase/17, 20-lyase activity and therefore are unable to convert 
progesterone to testosterone or androstenedione. In granulosa cell, testosterone or 
androstenedione is aromatized to estradiol by the P450arom enzyme (figure is based on 
description from Hanukoglus, 1992). 
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1.2 Control of follicular wave emergence  
 Using effective methods to synchronize follicular wave emergence is necessary to 
increase the degree of synchrony of estrus and ovulation for field application of 
reproductive management techniques such as fixed-time artificial insemination (Bo et al., 
1995b) and embryo transfer (Bo et al., 2002). Many protocols have been applied for this 
purpose. In the following paragraphs, there is a brief description about different protocols 
that are used for synchronization of follicular wave emergence in cattle. 
  
1.2.1 Gonadotrophin-releasing hormone-based protocols  
 Administration of GnRH or its analogues results in LH release that causes 
ovulation and luteinization of dominant bovine follicle present on the day of treatment 
(Macmillan and Thatcher, 1991). After the dominant follicle ovulates due to GnRH 
treatment, a new wave will emerge within 2 days. Based on previous work by 
Twagiramungu et al (1995), a protocol was developed that involves GnRH and PGF for 
synchronization of ovulation in lactating dairy cows; this protocol was named Ovsynch 
(Pursley et al. 1995). It consists of two injections of GnRH (9 days apart) and PGF on 
Day 7. Fixed-time AI was performed 12-18 hr after the second GnRH injection. GnRH-
based protocols appear to result in more synchronous ovulation than PGF alone. In one 
study, the Ovsynch protocol was compared with other protocols (single PGF injection or 
two PGF injections); Ovsynch-treated cows had higher pregnancy rates and fewer days 
open than other groups (33% and 107 d open for Ovsynch vs 12% and 122 d for the 
single injection, 11% and 129 d for two injections, and 6% and 116 d for untreated 
controls; Momcilovic et al., 1998). The Ovsynch protocol is used successfully with dairy 
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cows, but this program did not work very well with heifers (Pursley et al., 1995).  
  It was observed that the stage of follicle development or estrous cycle is a 
critical factor for ovulation to occur after the administration of GnRH (Martinez et al., 
1999; Vasconcelos et al., 1999). However, confirm that GnRH does not always result in 
ovulation or luteinization of the extant dominant follicle and, hence, it does not 
consistently induce the emergence of a new follicular wave (reviewed in Adams 1998). 
GnRH or LH treatment was given 3, 6, or 9 days after ovulation which correspond to the 
mid-growing phase, early static phase, or the late static phase of the dominant follicle. An 
influence on wave emergence was evident - 89 , 67 and 22 % heifers ovulated in Day 3, 6 
and 9 , respectively in GnRH.  Treatment with GnRH or LH was not associated with a 
consistent interval to new wave emergence (e.g., 3.1±0.7 days after treatment on Day 3 vs 
0.4±0.4 days when treated on Day 9) (Martinez et al., 1999). To improve the ovulation 
rate after first GnRH treatment, a presynchronization treatment has been suggested that 
would increase the probability of a dominant follicle capable of ovulating being present at 
that time; For this purpose, PGF is normally administered 12-14 days before the first 
GnRH (Moreira et al., 2001; Navanukraw et al., 2004) or a progestin device is placed in 
the vagina at the time of the first GnRH injection (Colazo et al., 2005a; Leitman et al., 
2008).  
 
1.2.2 Estradiol and progesterone  
  The combination of estradiol and progesterone has been used successfully for 
synchronization of estrus and ovulation (Bo et al., 1995b). In general, this protocol 
consists of an injection of estradiol at the time of insertion of a progesterone releasing 
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device (CIDR) that stays in place for 7-8 days. When the device is removed, a dose of 
prostaglandin is given to regress the existing CL and followed with AI 55-60 hours later 
(Martínez et al., 2004). It was observed that estradiol treatment suppresses follicle growth 
and this effect was profound when given in combination with progesterone (Bo et al., 
1994). The treatment worked by inducing the suppression of FSH release (Bo et al., 
2000). When estradiol is metabolized and blood levels decrease, FSH release results in 
emergence of a new follicular wave (Adams et al., 1992a; Bo et al., 1995a). The 
progesterone treatment during this method prevents ovulation by preventing the LH surge 
(Ireland and Roche, 1982) which can happen as a result of estradiol treatment. In 
addition, progestin treatment decreases LH release that assists in regression of the 
existing dominant follicle growth.  
 Different forms and esters of estradiol have been used for this purpose such as 
estradiol benzoate (Baruselli et al., 2004; Butler et al., 2011; Caccia and Bo, 1998; 
Martinez et al., 2005), estradiol valerate (D'Occhio et al., 1996; Mapletoft et al., 1999; 
Colazo et al., 2005b), unconjugated estradiol-17ß (Kastelic et al., 1997; Martínez et al., 
2005) or estradiol cypionate (Colazo et al., 2002; Sa Filho et al., 2009; Thundathil et al., 
1998). The different estradiol preparations have different abilities to synchronize wave 
emergence based on how long they remain in circulation and suppress FSH. In a 
comparative study, beef heifers were given 5 mg of estradiol-17ß or 1 mg of esrtadiol 
benzoate; both groups were treated with 100 mg of progesterone and a CIDR device was 
placed in the vagina. Estradiol-17ß and estradiol benzoate were equally effective to 
synchronized the follicular wave emergence and ovulation (Martínez et al., 2005). On the 
other hand, when estradiol valerate and estradiol cypionate were given as 5 mg and 1 mg 
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im injections, respectively, they showed lesser degree of synchronization for follicular 
wave emergence compare to estradiol-17ß (Colazo et al., 2002; Mapletoft et al., 1999). In 
addition, the ability of estradiol to synchronize the follicular waves can be affected by the 
dose of estradiol. When estradiol benzoate was given to CIDR–treated beef heifers at 
different dosages (1, 2.5, or 5 mg); the results indicated that 2.5 mg was more effective to 
synchronize the follicular wave than 5 mg (Caccia and Bo, 1998). In another study, 1 or 2 
mg of estradiol valerate in beef cows at CIDR insertion reduced the period between 
treatment and next follicular wave emergence compare to treatment with 5 mg (Colazo et 
al., 2005b).  
 
1.2.3 Follicle Ablation  
 Based on early studies involving electrocautery of ovarian follicles (Adams et al., 
1993b; Ko et al., 1991), physical ablation of follicles ≥ 5mm from both ovaries by 
transvaginal ultrasound–guided follicle aspiration has been used to synchronize follicular 
waves (Bergfelt et al., 1994). Destruction of dominant follicle removes the suppressive 
effect of estradiol on FSH concentration and a new surge of FSH occurs which stimulate 
a new wave emergence within 2 days (Adams et al., 1992a). Removing the two largest 
follicles was as efficient to synchronize the wave emergence as ablating all follicles ≥ 
5mm (Baracaldo et al. 2000). In another study, the ablation at random stages of estrous 
cycle followed by PGF 4 days later was used to synchronize ovulation (Bergfelt et al., 
1994). 
 Follicle ablation was also used with superovulation and embryo transfer (Bergfelt et 
al., 1997). In one study, ablation of the dominant follicle 48 hr prior to start of 
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superovulation treatment resulted in higher number of ovulations and embryos compared 
to superstimulation without ablation (Kim et al., 2001). In early lactation high-producing 
dairy cows, follicle ablation prior to superovulation in combination with progesterone and 
estradiol treatment resulted in collection of an acceptable number of transferred embryos 
(Amiridis et al., 2006). Although follicle ablation offers an efficient protocol to 
synchronize follicular waves, this method needs skill and special equipment making it 
difficult to apply widely in field conditions.  
 
1.3 Testosterone and follicular development 
1.3.1 Synthesis and metabolism 
Testosterone is a 19-carbon steroid hormone (Figure 1.3). In the female, the main 
sources of testosterone are theca cells and the adrenal gland (Vermeulen, 1998). LH 
controls the biosynthesis of testosterone in theca cells by activating the cyclic AMP 
pathway that increases transcription of encoding genes of enzymes for conversion of 
cholesterol to testosterone. Cytochrome P450 cholesterol side-chain cleavage 
(CYP450scc) is enzyme that converts cholesterol to pregnenolone (Figure 1.2b). Under 
the influence of two enzymes, 3ß-hydroxysteroid dehydrogenase (3ß-HSD; conversion of 
pregnenolone to 17α-hydroxypregnenolone) and 17α-hydroxylase 17,20 lyase 
(CYP17A1; progesterone and 17α-hydroxypregnenolone to androstenedione). Finally, 
androstenedione is converted to testosterone by 17ß-hydroxysteroid dehydrogenase (17ß-
HSD). Testosterone or androstenedione is transport to granulosa cells for conversion to 
estradiol by aromatase (Craig et al., 2011).  
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 Testosterone is metabolized mainly in the liver. Testosterone reaches the liver 
through systemic circulation where it undergoes biochemical reactions catalyzed by 
different enzymes leading to conversion of testosterone to inactive compounds such as 
androsterone and atiocholanolone (Henry and Norman, 2003).  
 
 
 
 
 
Fig. 1.3 Testosterone (C19 H28 O2) is a cyclo-pentano-phenanthrine structure 
consisting of 3 hexane rings and 1 pentane ring. 
 
1.3.2 Role of androgen receptors 
Although the role of testosterone as a substrate for estradiol in the female is well 
known, the direct effect of testosterone on the female reproductive system and follicle 
development is not clear. Androgen receptor (AR) protein exists in oocytes, granulosa 
cells, and theca cells of rodents, cattle, sheep, and pigs (Juengel et al., 2006; Walters et 
al., 2008). ARs are also present in luteinizing granulosa cells (Duffy et al., 1999) and 
increase after stimulation of ovulation (Chaffin et al., 1999). The expression of AR 
mRNA has been shown to change in granulosa cells depending on the stage of follicle 
development, e.g., AR mRNA is detected in preantral to early antral follicles in cattle 
(Hampton et al., 2004) and rats (Tetsuka et al., 1995), preantral to antral follicles in 
primates (Weil et al., 1998),  pigs (Slomczynska and Tabarowski, 2001), and preantral  
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dominant follicles in humans ( Suzuki et al , 1994; Horie et al., 1992). In addition, factors 
secreted from oocytes may modulate expression of the AR. In the large antral follicles of 
the rat, a gradient of AR immunostaining was detected - cumulus cells (close to oocyte) 
exhibited higher expression of AR protein compared with granulosa cells of peripheral 
layers (Tetsuka et al., 1995). Hormonal treatment has been reported to affect AR 
expression; in vivo treatment with testosterone resulted in increased AR expression in 
small antral follicles in primates and was correlated positively with expression of FSH 
receptors mRNA and proliferation, but negatively correlated with apoptosis (Weil et al., 
1998). Furthermore, when granulosa cells from macaque preovulatory follicle were 
treated with hCG, AR expression increaseed 24 and 36 hr post-treatment (Chaffin et al., 
1999) which may imply the role of androgen in preovulatory events. In general, these 
studies highlight the important role of AR activity in different stages of follicular 
development in different mammalian species. 
 
1.3.3 Role of testosterone in follicular development  
Many researchers have reported that androgens have stimulatory influence on early 
stages of follicular growth. When cattle preantral follicles were cultured and treated with 
testosterone, the transition of follicles from primary to secondary follicles was stimulated 
(Yang and Fortune, 2006). In vivo, when rhesus monkeys were treated with testosterone, 
the number of small follicles (primary, secondary, and tertiary follicles) was increased 
(Vendola et al., 1998) and the initiation of primordial follicles was stimulated (Vendola et 
al., 1999b).  
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Androgens also promote many ovarian growth factors that regulate the 
development of follicles. In vitro, testosterone treatment increases the granulosa cells 
responsiveness to FSH thereby increasing the production of estradiol (Hillier and De 
Zwart, 1981; Hillier et al., 1977). In vivo treatment of monkeys with testosterone elevated 
FSH receptor mRNA (FSH-R) expression (Weil et al., 1999) in the ovary; similarly 
dihydrotesteoterone increased the FSH-R expression in preovulatory follicles in gilts 
(Cardenas et al., 2002) which may modulate the responsiveness of the follicle to FSH 
(Drummond, 2006). In addition, testosterone and dihydrotestosterone ( DHT) treatment in 
primate ovaries enhance IGF-1 and IGF-1 receptors mRNA (Vendola et al., 1999a; 
Vendola et al., 1999b). Based on the above-cited literature, androgens appear to have a 
direct and crucial role in regulation of follicular growth.  
To determine the precise nature of effect of testosterone on follicular growth (i.e., 
whether observed effects are caused directly by testosterone or indirectly due to increased 
estradiol as a result of conversion from testosterone), researchers have conducted AR 
antagonist or aromatase blocker studies. Culturing preantral murine follicles with anti-
androgen serum or AR antagonist caused slow development for follicles compare to 
controls (Murray et al., 1998). In cattle, testosterone increased the transition from primary 
to secondary follicles and the use of an AR blocker (flutamide) suppressed this transition 
(Yang and Fortune, 2006). Furthermore, using aromatase blockers in the presence of 
androgen did not stop follicular growth (Walters et al., 2008) supporting the direct role of 
androgens in follicular growth during the early stages. During the follicular phase in pigs, 
testosterone treatment increased the number of preovulatory follicles and subsequent 
corpora lutea (Cardenas and Pope, 1994; Cardenas and Pope, 1997).  
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There are also reports that androgens can have an inhibitory effect on follicles. In 
an in vitro study, treatment of large antral follicles from primate ovaries with testosterone 
caused a suppression of FSH-stimulated aromatase activity (Harlow et al., 1988). It was 
also observed that dihydrotestosterone suppressed LH receptor formation on granulosa 
cells of rats through a post-cAMP mechanism (Jia et al., 1985). The atretogenic effect of 
testosterone may be mediated through enhanced apoptosis in granulosa cells of antral 
follicles (Billig et al., 1993; Daniel and Armstrong, 1986; Hillier and Ross, 1979 ; Kaipia 
and Heueh, 1997; Yuki Okutsu et al., 2010), resulting in suppressed steroidogenesis and 
follicle development. 
 
1.3.4 Effect of testosterone on gonadotrophin hormones  
 Many researchers have studied the effect of testosterone on gonadotrophins. 
When ovariectomized cows and mares were treated with testosterone, LH secretion 
decreased by 17% to 26% (Thompson et al., 1984). LH secretion was elevated by 
immununizing ewe (Campbell et al., 1990) or gilts (McKinnie et al., 1988) against 
androstenedione. Also, using 5 mg of testosterone propionate prevented ovulation due to 
a block of the LH surge in female rats (Hassani et al., 1978 ). In contrast, FSH 
concentrations increased when exogenous testosterone was given to ewe (Radford and 
Wallace, 1971) and gilts (Jimenez et al., 2008). 
In ruminants, LH concentrations in the blood reflects the changing in LH beta 
subunit mRNAs expression (Aspden et al., 2003; Wise et al., 1985). Studies in a rodent 
model indicate that testosterone or other androgen treatments modulate LH beta subunit 
mRNA expression in the pituitary gland and GnRH-mediated LH release (Keri et al., 
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1994; Krey et al., 1982; Yasin et al., 1996). These effects may be mediated by androgen 
receptor interaction with steroidogenic factor-1 (Curtin et al., 2001; Jorgensen and 
Nilson, 2001). These studies indicate that testosterone can have a direct negative impact 
on LH secretion through its effects on the pituitary gland. 
 
1.3.5 Testosterone applications in farm animals  
 Synthetic androgen compounds are used widely in feedlots in North America as 
growth promotants to increase the productivity of beef cattle, but this application has 
been banned recently in European countries due to health concern from steroid 
hormone residues in meat and milk (Holtz, 2009; Lone, 1997). In Canada, many types 
of implants growth have been approved to use with heifers and steers (Table 1.1). 
Testosterone and other androgenic compounds were also used to androgenize cows for 
estrus detection (Kesler et al., 1995; Nix et al., 1998). In pigs, testosterone treatment 
has been used to increase ovulation rate. Testosterone administration to gilts starting 
from Day 17 or 18 of cycle resulted in an increased ovulation rate (Cardenas and Pope, 
1994). Similarly, treatment from Day 13 of cycle increased ovulation rate and the 
percentage of blastocysts surviving (Cardenas and Pope, 1997).  
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 Table 1.1. Growth promotant implants approved for use in Canadian beef cattle (based  
on Agriculture Manitoba website (January  2012): 
http://www.gov.mb.ca/agriculture/livestock/beef/baa07s02.html   
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2.0 GENERAL HYPOTHESIS AND OBJECTIVES  
2.1 The objectives  
 
 The overall objective of this work was to determine the effect of exogenous 
testosterone treatment on ovarian function and hormone profiles in beef cattle. The 
specific objectives were: 
Objective 1:(Chapter 3) To evaluate plasma pharmacokinetics of testosterone to 
understand the residual depletion in blood of heifers after two injections of 
testosterone in an oil-based solution. 
Objective2: (Chapter 4) To determine the effect of testosterone administered at different 
phases of dominant follicle growth on: 
 i) The growth pattern of the extant dominant follicle, follicle numbers and 
emergence of subsequent follicular waves. 
 ii) Synchrony of wave emergence 
 iii) Systemic concentrations of FSH and LH  
iv) Luteal function 
 
2.2 The hypothesis  
  
 Administration of testosterone will shorten the life-span of the extant dominant 
follicle resulting in early and predictable emergence of a new follicular wave. 
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3.0 Plasma pharmacokinetics of testosterone in beef heifers after 
intramuscular administration of an oil-based preparation 
Al-Shanoon H, Chicoine A, Adams GP and Singh J 
 
Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, 
University of Saskatchewan, Saskatoon 
 
 
3.1 Abstract 
Plasma pharmacokinetics of testosterone were examined to understand the residual 
depletion in blood of heifers after two treatments of unconjugated testosterone in an oil-
based solution. Sixteen beef heifers were assigned to 4 groups (n=4 per group). Heifers 
were given intramuscular doses of 200 mg testosterone (in 4 mL canola oil) 12 hr apart 
on Day 1, 3 or 6 after ovulation (Day 0). The control group was given canola oil only. 
Blood samples were collected daily for 5 days and every second day thereafter until 13 
days after treatment. From a subset of animals (n=2 per group), blood samples were also 
collected at 0, 2, 4, 8, 12, 14, 16, 24 and 36 hr after treatment. There were no differences 
among the testosterone treated groups (P>0.14) in plasma testosterone concentrations 
after treatment, therefore data were combined as a single treatment group (n=16). Plasma 
testosterone concentrations increased rapidly within 2 hours (P<0.001) and then 
decreased slowly over 13 days. Maximum plasma testosterone concentration was 26.9 ± 
4.13 and 30.5 ± 4.07 ng/mL after the first and second doses, respectively. The time of 
maximum plasma concentration (Tmax) was 2 h after first and second treatments. The 
half-life of testosterone in circulation was 3.2 ± 0.6 days. Plasma testosterone 
concentrations of combined treatment group were no longer different from controls at 13 
days (0.5±0.08 and 0.2±0.05 ng/mL, respectively). In summary, intramuscular 
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administration of unconjugated (free) testosterone resulted in maximal plasma 
testosterone in within 2 hours, and a declined to pre-treatment concentrations within 13 
days.  
 
Keywords: Pharmacokinetics, testosterone, follicle development, cattle, anabolic steroid 
 
3.2 Introduction 
 
Many anabolic steroid hormones and their synthetic analogues have been used in 
food-producing animals to improve growth rate and fertility (Lone, 1997; Schmidely, 
1993). The routes of administration vary depending on the purpose and duration of use, 
e.g., testosterone can be given by intramuscular injections or subcutaneous implants (Nix 
et al., 1998) to have an effect over days to months. In addition to wide-spread use of 
testosterone as a growth promotant, it has been used to androgenize cows for detection of 
estrus (Nix et al., 1998) or as an atretogenic agent to regress the ovulatory follicle 
(Rajamahendran and Manikkam, 1994). Recent studies have used relatively high or 
multiple doses of testosterone (200 - 1500 mg total dose), but the pharmacokinetics of 
intramuscular administration of oil-based testosterone were not examined (Heekin and 
Kiracofe, 1983; Nix et al., 1998; Rajamahendran and Manikkam, 1994). Studies to 
document the dynamics of testosterone absorption and clearance may help to predict and 
refine appropriate testosterone dosage regimens for use in research and management in 
cattle. In addition, the pharmacokinetics of testosterone in food animals will facilitate 
estimation of the rate of testosterone residue depletion in the body and provide an 
estimate of the appropriate withdrawal periods after testosterone treatment (Lone, 1997). 
Steroid hormone residues in meat and milk has become a critical issue in many countries 
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as well as the use such products as performance enhancing substances in animals and 
humans (EC, 2003).  
In this study, we evaluated the plasma pharmacokinetics of testosterone to 
understand the residue depletion in blood of heifers after two intramuscular treatments of 
testosterone in an oil-based solution. This study was part of a larger experiment analyzing 
the effects of testosterone on follicular dynamics in heifers; the dose regimen was 
selected to provide a period of 24 to 48 hours of elevated testosterone concentrations in 
plasma. 
 
3.3 Material methods 
3.3.1 Experimental design  
The experiment was conducted on 16 post-pubertal beef heifers (Hereford cross) 
between April and August, at the University of Saskatchewan Goodale Research Farm. 
The heifers were between 12 and 14 months of age and weighed 338 ± 8.1 Kg (range, 
274-395 Kg). The heifers were fed alfalfa/grass hay and had water ad libitum during the 
experimental period. At the start of experiment, ovaries of all heifers were examined by 
transrectal ultrasonography (B-mode, 7.5 MHz linear-array transducer, MyLab Five, 
ESAOTE, Genova Italy) to detect the presence of a corpus luteum (CL). Heifers that had 
a CL, were given prostaglandin F2α im (500 µg of cloprostenol, EstrumateTM, Schering-
Plough Animal Health, Pointe-Claire, QC, Canada) to cause regression of extant CL 
(Hafs et al., 1974). Heifers were examined daily by transrectal ultrasonography to detect 
the day of ovulation (Day 0). Heifers were assigned randomly to one of four groups after 
ovulation to examine the effects of stage of the estrous cycle on plasma testosterone 
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kinetics. Heifers were treated with testosterone on Day 1, 3 or 6 after ovulation (n= 4 per 
group). The remaining heifers (n=4) were placed in a negative control group that received 
placebo injections. The experiment was approved by the University of Saskatchewan’s 
Animal Research Ethics Board, and adheres to the Canadian Council on Animal Care 
guidelines for humane animal use. 
 
3.3.2 Testosterone administration  
Five gram of unconjugated (i.e., non-esterified or free form) testosterone (Catalog 
# T-1500; Sigma Chemical Company, St. Louis, MO) was dissolved in 20 mL of benzyl 
alcohol and mixed with canola oil (No name®, Montreal, Quebec, Canada) to a volume 
of 100 mL (50 mg testosterone per mL solution). Heifers were given an intramuscular 
dose of 4 mL im (200 mg testosterone) in the gluteal muscles, for a dose range of 0.50 to 
0.73 mg testosterone/Kg body weight. The second dose was given 12 hours after the first. 
The dose of testosterone was estimated based on the results of previous studies in heifers 
(Nix et al., 1998; Rajamahendran and Manikkam, 1994). The control group was given 4 
mL im of canola oil, twice at an interval of 12 hours.  
 
3.3.3 Blood collection: 
Blood samples were collected via jugular venipuncture into heparinized vacuum 
tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA) from all heifers 
before the initial testosterone treatment, and at 1, 2, 3, 4, 5, 7, 9, 11, and 13 days after the 
initial testosterone treatment. In addition, two heifers in each treatment group and 3 
control heifers were selected randomly for intensive sampling over the first 24 hr after 
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testosterone administration. Blood samples were collected at 0, 2, 4, 8, 12, 14, 16, 24, and 
36 hr after the first testosterone treatment. The sample at 12 h was collected immediately 
before the second testosterone treatment). Blood samples were centrifuged at 3000 x g for 
10 minutes, and plasma was separated and stored in plastic tubes at -20 °C until assayed. 
 
3.3.4 Plasma testosterone radioimmunoassay (RIA): 
 A previously-validated solid-phase RIA procedure (Coat-A-Count Total 
Testosterone, Diagnostic Products, Los Angeles, California) was used to determine total 
plasma testosterone concentrations (Rawlings and Evans, 1995). The lower and upper 
limits of quantification were 0.1 ng/mL and 10 ng/mL, respectively. The intra-assay 
coefficient of variation was 4.8, 8.0, and 12.7% for low (1.61 ng/mL), medium (4.4 
ng/mL), and high (9.8 ng/mL) reference samples. The inter-assay coefficient of variation 
was 12.0, 14.2, 16.1% for low, medium and high reference samples, respectively.  
 
3.3.5 Pharmacokinetic analyses: 
The plasma testosterone concentration depletion rate for each heifer was analyzed 
using linear regression (Microsoft Excel 2007, Microsoft, Redmond, WA). Peak 
concentrations in plasma (Cmax) and times to peak concentration (Tmax) were determined 
using observed values from the intensive bleed concentration versus time curve.  The 
elimination half life (T1/2elim) of testosterone was calculated using the following formula:  
T1/2elim = ln(2) / kel  
where kel is the elimination rate constant (determined as the slope of the natural 
logarithmic plasma concentration versus time curve).  kel was determined using linear 
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regression of the elimination phase of each individual heifer’s plasma testosterone 
concentration versus time curve.  The elimination phase was comprised of plasma 
samples starting from 24 hours (Day 1) and included the subsequent daily plasma 
samples (Days 2 – 13).  The mean elimination half life of testosterone was calculated 
from the individual half-lives of all treated heifers.  
 
3.3.6 Statistical analyses: 
Plasma testosterone data were expressed as mean ± SEM. A repeated measurement 
model (Proc Mixed model on SAS, version 9.2) was used to determine whether 
differences in mean testosterone concentrations between treatment and control groups 
were different over time (P < 0.05). Based on Akaike information criterion, eight 
covariance matrices (AR, TOEP, ARH (1), TOEPH, CS, HF, SIMPLE, ANTE1) were 
examined to select the one best suited for final analysis (Littell et al., 1998). In an initial 
analysis, mean plasma testosterone concentrations over time between the treatment 
groups were compared (i.e., excluding control group) to determine if the data from these 
groups could be combined into one (combined) treatment group.  
 
3.4 Results 
Mean plasma testosterone concentrations in the three treatment groups did not differ over 
time (P = 0.47 and P = 0.14 for daily and hourly plasma samples, respectively), and 
groups were therefore combined into one treatment group. The mean testosterone 
concentration was higher testosterone-treated heifers compared to the control group (Fig. 
1) for both daily samples (P < 0.001) and hourly samples (P < 0.001).  
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In the six intensively-sampled heifers treated with testosterone, the observed 
maximum plasma testosterone concentration ranged from 18.4 to 41.7 ng/mL (mean ± 
S.E.M.: 28.7 ± 2.82 ng/mL) after the first treatment and 20.0 to 42.5 ng/mL (30.5 ± 4.07 
ng/mL) after the second treatment. Mean plasma testosterone concentrations immediately 
before the second treatment (12 hr after the initial treatment) was 10.9 ± 1.92 ng/mL 
(range: 19.2 to 7.2ng/mL) in testosterone-treated heifers, and was higher (P<0.001) than 
the pre-treatment (time 0) sample in control heifers (0.02.± 0.006 ng/mL). The value of  
plasma testosterone concentrations after the second dose resulted from interaction 
between the accumulation of testosterone from the first  and second injections . Plasma 
testosterone concentrations within 36 hr after the first testosterone treatment (i.e., 24 hr 
after the second injection) were 8.1 ± 1.37 ng/mL (range: 4.4 to 10.1 ng/mL) 
The time of maximum plasma concentration ( Tmax) was 2 hr in 4 of 6 heifers after 
the first injection and 4hr in the remaining 2 heifers. The time of maximum plasma 
 (treatment ) was 2hr in 5 of heifers after the second injection and 4 hr in the sixth heifer.  
The other 3 had an observed Tmax at 4 hours. The mean elimination half-life of 
testosterone in the combined treatment group was 3.2 ± 0.6 days. On Day 13, there was 
no significant difference in mean testosterone concentrations between the treatment group 
and control (0.5±0.08 and 0.2±0.05 ng/mL respectively).  
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Fig. 3.1 Changes in plasma testosterone concentrations (mean ± SEM) in heifers for the 
first 36 h (Fig A) and 13 days (Fig. B) after intramuscular administration of unconjugated 
testosterone in oil (n= 12) or placebo (n=3). Two treatments were given at a 12-hour 
interval (indicated by arrows). T=Treatment, D=Day, H=hours, T*D and T*H = 
interaction between time and treatment.  
 
3.5 Discussion 
Testosterone has been used in farm animals to improve growth and daily weight 
gain (anabolic effect), to prevent estrus expression in heifers and to create teaser-cows for 
estrus detection . For these purposes, long-acting, esterified forms of testosterone have 
been used either as oil-based injections or subcutaneous implants, and the 
pharmacokinetics of these forms have been studied (Lone, 1997). The objective of this 
study was evaluating some of the pharmacodynamic parameters of short-acting, non-
esterified testosterone in cattle and provide drug distribution data for study of 
reproductive functions. To keep testosterone concentration above 5 ng/mL for the first 36 
hours followed by decline (to obtain biological effects for the purposes of the follicle 
dynamics study) in this study, two injections of testosterone were required at 12 hr 
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intervals. We found that the maximum plasma testosterone concentration (Cmax) was 
between 2 and 4 hr after a single intramuscular injection of 200 mg of oil-based 
unconjugated (free) testosterone and the mean distribution half-life (t ½) of testosterone 
was 3.2 ± 0.6 days and the drug depleted to baseline within 2 weeks. 
The absorption of esterified testosterone into bloodstream is slow because the 
ester group lowers water solubility of testosterone leading to prolonged release into 
circulation. For this reason, most anabolic androgens used as growth promotants in cattle 
or other farm animals are esters (Nix et al., 1998; Lone, 1997; Pugh et al., 2004; Traish et 
al., 2009). This study was part of research that focused on the effects of testosterone on 
ovarian follicular dynamics, dominant follicle regression and synchronization of 
follicular waves. For that reason, we needed a short-acting testosterone preparation that 
would provide a rapid increase in the blood within hours, maintain relatively high-levels 
for 36 hr followed by rapid decrease to baseline. Therefore, unconjugated testosterone 
was selected and injected twice at 12 hr interval. Testosterone concentrations increased 
rapidly after injection to reach peak values after 2 hours and plasma levels remained 
above 17.43 ng/mL for the first 36 hrs in all animals. The pattern of testosterone increase 
in blood in this study was consistent with results of another study (Rajamahendran and 
Manikkam, 1994) where the same form testosterone was used in heifers. The elimination 
half life of testosterone in this study also illustrates the difference in testosterone 
pharmacokinetics from other studies where ester formulations were used. In this study, 
the elimination half-life was testosterone was relatively short (3.2 days) compared with 
testosterone esters e.g., 21.7±1.1 days for testosterone undecanoate (Zhang et al., 1998) 
and 10.3±1.1 days for testosterone enanthate (Partsch et al., 1995). 
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The European Union has banned several steroid hormones that could be used as 
growth promotants in livestock because of concerns of the effects of milk and meat 
residues on human health (EC, 1996). Many types of growth implants contain ester 
groups of anabolic steroids (Lone, 1997) that cause release of the hormone slowly over a 
prolonged period of time; the communication between the tissues and steroid hormones 
over time increases the residual compounds in the tissues. In our study, injectable 
unconjugated testosterone, which results in rapid release into the circulation, also resulted 
in rapid testosterone depletion; testosterone concentrations in treatment groups returned 
to pretreatment concentrations within 13 days. Although the residual of testosterone in 
tissues was not examined in this study, the rapid decline of testosterone in plasma 
indicates that residuals in tissue may also be reduced. Several studies have alluded to the 
positive relationship between specific compounds in plasma and residuals in tissue. In a 
study in pigs, researchers investigated the relationship between the level of olaquindox 
(growth promoter) in plasma and tissue through a marker residue (methyl-3quinoxaline-
2-carboxylic acid); they found the correlation coefficient between tissue and plasma 
concentrations was 0.92 (Yang et al., 2010). In another study, broiler chickens were given 
moxifloxacin intramuscularly; the drug disappeared from plasma and tissue within 120 
hours post-treatment (Goudah, 2009). These studies indicated a positive relationship 
between the level of drug in the blood and its residual in tissue. In this regard, using 
unconjugated testosterone as a treatment in cattle may be acceptable if the short duration 
of drug in plasma is considered and if the withdrawal period is longer than 2 weeks. 
However, we could not approve same relationship between the residuals of drugs in 
plasma and tissue; more research is needed to determine the residual of drug in the tissue. 
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In summary, administration of 200 mg of unconjugated testosterone in oil resulted 
in elevated plasma concentrations within 2 to 4 hr with a Tmax of 26.9 ± 4.13 ng/mL; 
plasma levels decreased to 10.9 ± 1.92 ng/mL by 12 hr. By giving a second injection of 
200 mg testosterone 12 hr after first injection, plasma testosterone concentration were 
maintained above 5 ng/mL for a 48 hour period. Thereafter, plasma testosterone 
concentrations decreased quickly with depletion half-life of 3.2 days in bloodstream and 
levels returned to baseline by 13 days. The relatively short period of elevated plasma 
concentrations of testosterone suggest its possible use in treatment protocols in cattle, but 
intensive pharmacokinetic studies are needed to determine the fate of drug in tissues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
	   36	  
4.0 Effect of Testosterone on Dominant follicle Growth and Luteal 
Dynamics in Beef Heifers 
 
Al-Shanoon H1, Yapura J1, Adams GP1, Mapletoft RJ2 and Singh J1 
Department of Veterinary Biomedical Sciences1 and Department of Large Animal 
Clinical Sciences2, Western College of Veterinary Medicine, University of 
Saskatchewan, Saskatoon 
 
4.1 Abstract: 
The study was designed to determine the effects of testosterone on ovarian 
function in cattle. We tested the hypothesis that administration of testosterone will 
shorten the life-span of the dominant follicle resulting in early emergence of a new 
follicular wave. Experiment 1 was conducted to select the testosterone formulation (free 
or esterified testosterone) that would increase circulating testosterone concentrations 
within a very short interval and would last for at least 24 hours.  Results indicated that the 
treatment with the unconjugated form of testosterone (free testosterone; n=4) in oil 
increases the testosterone concentration in blood very rapidly compared to an esterified 
form (testosterone enanthate; n=4). Therefore, unconjugated testosterone in oil was 
selected for use in Experiment 2 in which the effect of exogenous testosterone treatment 
on different days of the first follicular wave on ovarian function in cattle was examined. 
Beef heifers were assigned at random to four groups (n=6 per group). Heifers were given 
an intramuscular injection of 200 mg of unconjugated testosterone in 4 mL canola oil 
twice at 12 h intervals on the Days 1, 3 or 6 after ovulation (Day 0). The control group 
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was given im canola oil only (n=6; n = 2 on each of the 3 treatment days). Ovarian 
structures were monitored daily by transrectal ultrasonography for one interovulatory 
interval. Following treatment, the dominant follicle grew slower for the next 5 days in 
treatment Day 1(T1; P=0.05) and Day 3( T3; P=0.06) groups compared to the control 
group, while the dominant follicle in Day 6 (T6) group regressed more slowly (P=0.02) 
compared to the control group. The diameter profile of the dominant follicle of the post-
treatment wave (Wave 2) and the ovulatory wave did not differ between treatment groups 
and the control group. Overall, testosterone treatment extended the duration of current 
wave (Wave 1; P=<0.001) and the post-treatment wave (Wave 2; P=0.02) compared with 
the control group. Although the interovulatory interval was not affected by the 
treatments, the proportion of 2-wave cycles tended to be higher (P=0.08) after 
testosterone treatment compared to the control group. Mean LH concentrations were 
lower in T1 and T3 groups compared to the control group, while LH concentrations were 
not affected in the T6 group. Testosterone treatment did not affect circulating FSH 
concentrations, or the number of follicles (4-5 mm, 6-8 mm or ≥ 9 mm) within the first 
follicular wave. Corpus luteum diameter during the first 12 days of the treatment cycle 
did not differ between testosterone-treated and control groups, but rate of regression of  
corpus luteum during the regression phase (Days 15-18) in treatment groups was faster 
(P<0.05) compare to the control group. In conclusion, our hypothesis that testosterone 
treatment will shorten the life-span of dominant follicle was not supported. Treatment 
with testosterone resulted in slower growth of the dominant follicle when treatment was 
initiated at or before the time of dominant follicle selection, and slower regression of the 
dominant follicle when treatment was initiated after selection during early static phase. In 
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addition, treatment with testosterone delayed the emergence of the next follicular wave 
irrespective of the status of the dominant follicle at the time of treatment. 
Keywords: Testosterone, follicle development, cattle, corpus luteum, ultrasonography, 
follicular and luteal dynamics, FSH, LH,  
 
4.2 Introduction 
Synchronization of follicular wave emergence has garnered the interest of 
researchers because it is a prerequisite in many reproductive techniques such as ovarian 
superstimulation, and fixed-time artificial insemination. Most methods to control 
follicular waves depend on removing the effect of the existing dominant follicle by using 
hormonal treatment (progesterone, estradiol; Martínez et al., 2004), ultrasound-guided 
follicle ablation (Bergfelt et al., 1994), or inducing ovulation with GnRH (Twagiramungu 
et al, 1995; Pursley et al., 1995; Martinez et al., 1999). The Ovsynch protocol is one of 
the most commonly used methods for ovarian synchronization (Pursley et al., 1995; 
Whisnant et al., 2000) and involves GnRH treatment to induce ovulation of the dominant 
follicle followed by emergence of a new follicular wave 2 days later (Twagiramungu et 
al., 1995)., Cows are treated with .prostaglandin on Day 7 after the first GnRH to cause 
luteolysis. A second GnRH injection is given on Day 9 to induce ovulation for fixed-time 
artificial insemination. However, the effect of GnRH-based protocols is dependent on the 
stage of development of the dominant follicle (Martinez et al., 1999) or stage of the 
estrous cycle (Vasconcelos et al., 1999) when treatment is given. Estradiol alone or in 
combination with progesterone has been highly effective in synchronizing follicle wave 
emergence in cattle (Martínez et al., 2004) because it does not depend on the status of the 
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extant dominant follicle. Exogenous estradiol reduces FSH secretion, and LH pulse 
frequency and amplitude in cattle (Ginther et al., 2000) leading to regression of antral 
follicles and emergence of a new wave once the suppressive effect of estradiol on FSH 
ceases, on average 4 days later (Bo et al., 1995b; Bo et al., 1995a). However, many 
countries including those in European Union, have banned the use of estradiol in food-
producing animals because of potential human health concerns of hormone residues in 
meat and milk (Lane et al., 2008). As a result, finding alternative treatment that can be 
used effectively for the synchronization of follicular wave emergence has become a 
pressing need. 
 Testosterone may be an acceptable alternative to estradiol. Testosterone is 
involved in the regulation of ovarian function (Walters et al., 2008) through activation of 
androgen receptors that are localized  in granulosa cells and stromal cells (Drummond, 
2006). Further, testosterone increases aromatase enzyme expression in granulosa cells in 
vitro (Wu et al., 2011). Therefore, exogenous testosterone may increase endogenous 
estradiol concentration by increasing aromatase activity and by providing readily 
available substrate for aromatization. This, in turn, would exert a negative feedback effect 
on the hypothalamic-pituitary axis leading to suppression of gonadotrophin hormone (LH 
and FSH) release (Ginther et al., 2000; Roos et al., 1980; Toranzo et al., 1989). In 
addition, testosterone can have additive direct suppressive effect on circulating levels of 
gonadotrophins via direct negative feedback on the hypothalamus and pituitary glands 
(Gross, 1980; Handa et al., 1986; Roselli et al., 1990). Since testosterone reduces LH 
pulse amplitude and suppress FSH release (Jorgensen and Nilson, 2001; Martínez et al., 
2004) and may cause the extant dominant follicle to regress.  
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  Testosterone has been used as a treatment in farm animals for different purposes. 
It has been injected in different forms to produce androgenized cows that can be used for 
the detection of estrus (Nix et al., 1998). Compared to implants, injectable testosterone 
was found to be a reliable method to induce “teaser animals” (Heekin, 1983; Kiser et al., 
1977). Heifers treated with 200 mg of testosterone per day for 4 days during follicular 
phase induced preovulatory follicle atresia (Rajamahendran and Manikkam, 1994). In 
addition, testosterone has been used to increase ovulation rate in postpubertal gilts 
(Cardenas and Pope, 1994; Cardenas and Pope, 2002). Based on above-cited information, 
it is reasonable to presume that testosterone may synchronize the emergence of the next 
follicular wave by causing demise of the dominant follicle present at the time of 
treatment. 
The present study was designed to find alternative protocols to control ovarian 
follicular wave dynamics in cattle, and in particular, determine the effect of testosterone 
on follicular dynamics. The objective of this experiment was to determine the effect of 
exogenous testosterone treatment on different days of the first follicular wave on ovarian 
function in cattle. We tested the hypothesis that the administration of testosterone will 
shorten the life-span of the extant dominant follicle resulting in early emergence of a new 
follicular wave.  
 
4.3 Materials and methods  
Two experiments were conducted between April and August, at the University of 
Saskatchewan Goodale Research Farm. Eight Holstein cows were used in Experiment 1, 
and 24 post-pubertal beef (Hereford-cross) heifers were used in Experiment 2. The 
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animals were fed alfalfa/grass hay and had water ad libitum during the experimental 
period. This work was approved by the University of Saskatchewan’s Animal Research 
Ethics Board, and adheres to the Canadian Council on Animal Care guidelines for 
humane animal use. 
 
4.3.1 Hormone preparations: 
Five grams of unconjugated (free) testosterone (Catalog # T-1500; Sigma 
Chemical Company, St. Louis, MO) were dissolved in 20 mL of benzyl alcohol and then 
mixed with canola oil (No name®, Marques de Commerce de Loblaws INC., Montreal, 
Quebec, Canada) to make a final volume of 100 mL (50 mg testosterone per mL). 
Testosterone enanthate was supplied by the manufacturer in liquid form containing 200 
mg of testosterone enanthate per mL of sesame oil. 
 
4.3.2 Experiment 1 - Pilot study 
The aim of the pilot study was to select a suitable testosterone preparation and 
dose for Experiment 2. We measured plasma testosterone concentrations after cows were  
treated with one or two injections of 200 mg of  unconjugated testosterone (free-form) or 
200 mg of esterified form of testosterone (testosterone enanthate, DelatestrylTM, 
Theramed Corporation, Mississauga, Canada). On random days of the follicular wave, all 
follicle ≥5 mm were aspirated using transvaginal ultrasound-guided puncture (ablation). 
Cows (n=2 per group) were assigned to testosterone or testosterone enanthate groups and 
were given either a single intramuscular (im) injection 4 days after ablation or two im 
injections with 24 hours apart starting 3 days after ablation. Blood samples were collected 
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by jugular venipuncture into 10 mL heparinized vacuum tubes (Becton Dickinson 
Vacationer Systems, Franklin Lakes, NJ, USA) at 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 
120, 288 hr post-treatment (time of treatment = 0hr). Five additional blood samples were 
collected 25, 26, 28, and 36 hr post-second treatment for groups that were given two 
injections. Plasma samples were stored at -20 °C until assayed for testosterone.  
 
4.3.3 Experiment 2 – Effects on ovarian and hormonal dynamics 
4.3.3.1 Animals and treatments: 
Twenty-four beef heifers (Hereford-cross) between 12 and 14 months of age and average 
weighing between 273 and 404 Kg (340 ± 0.5Kg) were selected from a herd of 40 heifers 
following transrectal ovarian ultrasonography (B-mode, 7.5 MHz linear-array transducer, 
MyLabTMFive, ESAOTE, Genova, Italy) based on the presence of a CL. 
 All 24 heifers were given prostaglandin (500 µg of cloprostenol, EstrumateTM, 
Schering-Plough Animal Health, Pointe-Claire, QC, Canada) im to regress the CL (Hafs 
et al., 1974). Heifers were examined daily by transrectal ultrasonography to detect the 
day of ovulation (Day 0). After ovulation, heifers were assigned randomly to one of four 
groups. Heifers in the three treatment groups were given 200 mg of unconjugated 
testosterone in 4 mL canola oil im twice, at 12 h intervals, on Days 1, 3 or 6 of first 
follicular wave. The preparation and dose of testosterone was selected based on results 
from Experiment 1. The control group (n=6) was given 4 mL canola oil im on the 
corresponding days of treatment, n=2 heifers each on Day 1, Day 3 or Day 6.  
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4.3.3.2 Ovarian ultrasonography: 
Ovarian structures were monitored daily by transrectal ultrasonography during the 
period between two consecutive ovulations (interovulatory interval). Sketches of both 
ovaries were made during each examination to record the number, position and diameter 
of follicles ≥ 4 mm and CL diameter during one interovulatory interval. The total number 
of follicles ≥ 4 mm in both ovaries was counted starting from wave mergence. Ovulation 
was determined by the disappearance of a follicle ≥ 8 mm between two consequential 
examinations, followed by formation of a CL (Pierson and Ginther, 1987b). Wave 
emergence was determined retrospectively and was defined as the day when the future 
dominant follicle was first detected between 4 and 5 mm in diameter with the a 
concurrent increase in the number of 4-5 mm follicles (wave emergence; Ginther et al., 
1996a). The dominant follicle was recognized as the largest antral follicle after selection 
(Ginther et al., 1989b). Day of CL regression was defined as the first day when luteal 
diameter was seen to decrease constantly over 3 consecutive days (Adams et al., 1993a). 
The interwave interval of wave 1 and 2 was the interval between the emergences of two 
consecutive waves while in the ovulatory wave, it was the interval between the wave 
emergence and ovulation 
 
4.3.3.3 Blood collection: 
Blood samples were collected into heparinized vacuum tubes (Becton Dickinson 
Vacutainer Systems, Franklin Lakes, NJ, USA) twice daily (morning and evening) 
starting from pre-treatment ovulation until post-treatment ovulation (interovulatory 
interval). Blood samples were also collected at 0, 2, 4, 8, 12, 14, 16, 24, 36, 48, 60, and 
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72 h post-treatment into vacutainer tubes. All samples were centrifuged at 3000 x g for 10 
min; plasma was separated and stored in plastic tubes at -20 °C until assayed. 
 
4.3.4 Hormone radioimmunoassay: 
 A solid-phase radioimmunoassay (Coat-A-Count Total Testosterone, TKTT2, 
Diagnostic Products) was used to determine total testosterone concentrations (Rawlings 
and Evans, 1995). For Experiment 1, all samples were analyzed in a single assay. The 
range of the standard curve was 0.1 to 10 ng/mL. The intra-assay coefficients of variation 
were 6.5%, 3.5%, and 13.2% for low (1.25 ng/mL), medium (3.50 ng/mL), and high 
(7.09 ng/mL) reference samples. Similarly, all samples from Experiment 2 were analyzed 
in a single assay and the intra-assay coefficients of variation were 4.79%, 8.04%, and 
12.65% for low (mean, 1.61 ng/mL), medium (mean, 4.45 ng/mL), and high (mean, 9.80 
ng/mL) reference samples.  
 Plasma FSH concentrations were measured in duplicate using a double-antibody 
radioimmunoassay (Rawlings et al., 1984). The primary antibody was NIDDK-anti-
oFSH-1 and the concentrations were expressed as USDA bovine FSH-Il units. The range 
of the standard curve was 0.12 to 16 ng/mL. The intra-assay coefficients of variation 
were 10.7% for low reference samples (mean, 1.61 ng/mL) and 6.8% for high reference 
samples (mean 3.33 ng/mL).  
 Plasma LH concentrations were measured in duplicate using a double-antibody 
radioimmunoassay and were expressed as NIDDK-bLH4 units (Evans et al., 1994a). The 
range of the standard curve was 0.06 to 8.0 ng/mL. The intra-assay coefficients of 
variation were 10.9% for low reference samples (mean, 1.16 ng/mL) and 8.1% for high 
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reference samples (mean, 2.48 ng/mL).  
 Progesterone concentrations were determined in a single assay using a solid-phase 
radioimmunoassay (Coat-A-Count®, Catalog number TKPG5, Diagnostics Products 
Corporation, Los Angeles, USA) with a sample volume of 100 µL (Rawlings et al., 
1984). The range of the standard curve was 0.1 to 40.0 ng/mL. The intra-assay 
coefficients of variation were 9.6% (mean, 1.47 ng/mL), 7.06% (mean, 3.50 ng/mL) and 
6.40% (mean, 24.27 ng/mL) for low, medium and high reference samples, respectively. 
 
4.3.5 Statistical analyses: 
Data were centralized to wave emergence and analyzed by repeated measures 
procedures, using the Statistical Analysis System software package (SAS program, 
version 9.2). Hormone data (LH, FSH, testosterone, progesterone) and follicular data 
(diameter of dominant follicles and CL, number of follicles within a wave) were analyzed 
using Proc Mixed repeated measurement for effect of testosterone treatment, day, and the 
interaction between day and treatment. The concentrations of LH and FSH before (Day -1 
and Day 0) and after (Days 1 to 5) treatment were analyzed using one-way ANOVA 
between treatment combined group (T1, T3 and T6 combined) and the control group. To 
identify changes in follicle numbers, follicles were categorized according to diameter (4-
5 mm, 6-8 mm and ≥ 9 mm). During an interovulatory interval, data for CL diameter 
were divided into three portions (Days 1-6, 7-12 and 13-18 after ovulation) to represent 
growing, functional and regression phases. Data for each portion were analyzed 
separately. Single point measurements (interovulatory interval, interwave interval, 
number of waves in the interovulatory interval, day of cuprus luteum regression) were 
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analyzed by one-way analysis of variance and/or two sample t-test analysis. The growth 
rate of dominant follicle for each day was calculated by subtracting the diameter of the 
previous day from the current day. Proportions (i.e., proportion of two-wave cycles) were 
analyzed by Glimmix procedure using binary distribution. When no differences were 
found among treatment groups, data were combined and re-analyzed as a single treatment 
group (combined treatment  group).  
To determine synchrony of emergence of the second wave, data on day of 
emergence was tested using Bartlett test to check the homogeneity of variance among 
groups. The deviation on day of wave emergence from the group mean was calculated. In 
order to understand the variation in time of emergence of the second wave in treatment 
groups .The heifers were assigned to two groups: One group included heifers in which 
emergence of the second wave occurred before Day 12 of the interovulatory interval (TN, 
n= 9) and the other group included heifers in which the second wave emerged after Day 
12 (TD, n=8). Data on LH and FSH concentrations were transformed to a percentage of 
the mean concentration determined in the first two samples (i.e., Days 0 and 1) for each 
individual heifer before analysis of variance for repeated measures. One heifer was 
excluded from the T6 group because of very early wave emergence. All values are 
expressed as mean ± SEM and probability (P) values of ≤0.05 were considered 
statistically significant difference. 
 
 
 
	   47	  
4.4 Results  
4.4.1 Experiment 1- Pilot Study 
Mean plasma concentrations of testosterone across time for Experiment 1 are 
shown in Figure 1. Plasma testosterone profiles differed between the two types of 
testosterone when given either as a single (Fig. 5.1A, P=0.006) or two injections (Fig. 
5.1B; P= 0.01). Following the first injection of unconjugated (free) testosterone, plasma 
testosterone levels increased more than 10 fold within 1 h from 1.1 ± 0.39 to 15.7 ± 2.01 
ng/mL followed by a decrease to 8.6 ± 0.70 ng/mL by 12 h and to 3.4 ± 0.24 ng/mL 
within 24 h (combined data from Fig. 1A and 1B). Following the second injection (Fig. 
5.1B), testosterone concentrations increased from 3.6 ± 0.45 to 19.6 ± 0.53 ng/mL within 
1 h and dropped rapidly as observed following the first injection. In the testosterone 
enanthate groups, the plasma levels of testosterone increased gradually after treatment 
from 0.3± 0.18 to reach a maximum of 1.2 ± 0.47 ng/mL 8 h post-treatment (with single 
injection). After the second injection (Fig. 5.1B), plasma levels of testosterone increased 
from 1.1 ± 0.04 ng/mL at the time of second injection to reach a maximum of 2.3 ± 0.24 
ng/mL at 36 hr. Based on the results obtained in Experiment 1, we decided to treat heifers 
in Experiment 2 twice at 12 h intervals with unconjugated free testosterone in oil. We 
predicted that plasma testosterone levels would remain above 8 ng/mL for 24 h followed 
by a sharp decline 
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    Fig. 4.1. Plasma testosterone concentrations (mean ± SEM) after treatment with 
testosterone. In In Experiment 1, single im injection (Fig. A) or two injections (24 hr 
apart, Fig. B) of 200 mg unconjugated testosterone (testo) or testosterone enanthate 
(TE) were given to cows. Times of treatment are indicated by obligue arrows.  In 
Experiment 2, (Fig. C) heifers (n=6 per goup) on Days 1 (T1), Day 3(T3), and Day 6 
(T6) after ovulation were treated with 2 injections of unconjugated testosterone 12 hr 
apart. Control group heifers were given placebo ( 4ml canola oil) treatment. There was 
no difference in plasma testosterone concentration among the three testosterone groups, 
therefore the combined data from D1, D3 and D6 groups versus control  are presented 
(Fig D). P-values for treatment (T), day (D) and treatment*time interaction (T*D) are 
indicated on the graphs.  	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4.4.2 Experiment 2- Effects on ovarian and hormonal dynamics 
Results are summarized in Tables 4.1 and 4.2, and Figures 4.2 to 4.9. By design, 
when there was no difference among testosterone groups, data were combined into a 
single group (combined treatment group) for analysis. 
 
4.4.2.1Plasma testosterone concentrations  
Mean plasma concentrations of testosterone over time are shown in Fig. 4.1C and 
4.1D. Mean concentrations of testosterone over the first 5 days following treatment were 
6.0 ± 0.93, 5.8 ± 0.67, 4.8 ± 0.58 and 0.2 ± 0.03 ng/mL for T1, T3, T6, and C groups, 
respectively (P<0.001; Fig.5.1 C). Plasma testosterone concentration were 12.4 ± 0.16 
ng/mL 24 h after the first treatment (testosterone treatment groups combined, Fig 1 D), 
and then decreased rapidly to 6.1 ± 0.17 ng/mL by 48 h and continued to decrease over 
the next 3 days. Testosterone concentrations in the control group remained at a constant 
low level during the same period of time.  
 
4.4.2.2 Interwave and interovulatory intervals 
No differences were detected between groups for the first interwave interval 
(Table 4.1), but when combined data from testosterone treatment groups were compared 
to control (Table 4. 2), a prolonged interval between the emergence of first and second 
wave (P=0.001) was detected. The second wave interwave interval for T1 was longer 
(P=0.05) than control, but did not differ from other treatment groups (Table 1). Overall, 
testosterone treatment (T1, T3 and T6 combined), extended (P=0.02) the second wave 
interwave interval  compared to control (Table 2). The interwave interval of the ovulatory 
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wave was longer (P=0.04) in the T6 group compare to controls (Table1), while T1 and 
T3 were intermediate and not different from either; however, combined data for all 
testosterone treatment groups did not differ (P=0.10) from the control group (Table 2).  
The duration of the interovulatory interval did not differ among groups (Table 1, 
P= 0.23) or when treatment group data were combined and compared to the control group 
(Table 2, P= 0.28). Also, the number of waves in an interovulatory interval did not differ 
among groups (Table 1, P= 0.19) or between the combined treatment group and the 
control group (Table 2, P=0.10). Although the proportion of 2 wave cycles was 
numerically higher in testosterone treatment groups compared to the control group, the 
difference was not significant (Table 1, P=0.27). However, when testosterone treatment 
groups were combined (Table 2), there was a tendency for more 2-wave cycles after 
testosterone treatment compared to control group (P=0.08).  
Table 4.1. Mean (±SEM) of different ovarian parameters in controls and treatment groups on 
Day 1 (T1), Day 3  (T3), and Day 6 (T6). n = number of animals in each group 	  
Testosterone treatment Item Control 
Day 1 Day 3 Day 6 
Interovulatory interval 21.7±1.35 
(n=6) 
28.7±4.14 
(n=6) 
21.4±0.7 
(n=5) 
21.8±2.84 
(n=4) 
Interwave interval (Wave 1) 8.7±0.42 
(n=6) 
12.0±1.32 
(n=6) 
11.2±1.0 
(n=6) 
12.2±1.68 
(n=5) 
Interwave interval (Wave 2) 7.3±0.49b 
(n=6) 
11.7±1.76a 
(n=6) 
7.8±0.75ab 
(n=6) 
9.8±1.16ab 
(n=5) 
Interwave interval (last wave) 6.8±0.40a 
(n=6) 
9.0±0.73ab 
(n=6) 
7.0±0.83ab 
(n=5) 
9.4±0.92b 
(n=4) 
Proportion of 2 wave cycles 1/6 
(17%) 
4/6 
(67%) 
3/6 
(50%) 
4/5 
(80%) 
CL life-span* (days) 
 
15.9±1.31 
(n=6) 
14.5±0.96 
(n=6) 
13.8±1.40 
(n=6) 
12.6±0.97 
(n=5) 
ab Within rows, values with no common superscripts are different (P≤0.05) 
* Interval from ovulation to the day when CL began to regress 
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4.4.2.3 Follicular dynamics  
The diameter profile of the dominant follicle in different waves is shown in Fig. 
4.2 During the first follicular wave (Fig. 4.2A), testosterone treatment affected the 
diameter of the dominant follicle (P= 0.02) in a phase-specific manner. However, 
testosterone treatment did not alter the dominant follicle diameter in the next wave (Fig. 
4.2B, P=0.83) or the ovulatory wave (Fig. 4.2C, P=0.26). For the first wave dominant 
follicle, daily growth rate (Fig 4.3A and 4.3B) and mean growth rate over 5 days 
following treatment on Days 1 or 3, (Fig. 4.3D and 4.3E) were suppressed significantly 
Table 4.2 Mean (±SEM) ovarian parameters of controls and combined testosterone treatment 
groups, n= number of animals.	  	  
 
Variables 
 
Control 
 
Treatment 
 
P- value  
Interovulatory interval 21.6±1.35 
(n=6) 
24.4±2.07 
(n=15) 
0.28 
Interwave interval (Wave 1) 8.7±0.42 
(n=6) 
11.8±0.72 
(n=17) 
0.001 
Interwave interval (Wave 2) 7.3±0.49 
(n=6) 
9.8±0.81 
(n=17) 
0.02 
Interwave interval (last wave) 6.4±0.40 
(n=6) 
8.3±2.02 
(n=15) 
0.10 
Number of wave in IOI 
 
  
3.0±0.25 
(n=6) 
 
2.4±0.19 
(n=15) 
0.10 
 
 
Proportion of 2-wave cycle 1/6   
(16.66%) 
11/17 
(64.70%) 
 
0.08 
CL life-span*  
 
15.7±1.3 
(n=6) 
13.7±0.63 
(n=17) 
0.14 
* Interval from ovulation to the day when CL began to regress  	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compared to the control group. Following testosterone treatment on Day 6, the dominant 
follicle regressed slower than in the control group (Fig.4.3C and 4.3F; P= 0.03). 
 
 
 
 
Fig. 4.2. Dominant follicle diameter profile (mean ± SEM) of first, second, and ovulatory 
waves. Treatment groups T1, T2 and T3 were given 200 mg of free testosterone twice (at 
12 hr intervals) on Days 1, 3 or 6 respectively of the first follicular wave, respectively 
while control (C) group was given placebo (coanola oil) treatment. P-values for treatment 
(T), day (D) and treatment*time interaction (T*D) are indicated on the graphs. ? 
indicates differences between the treatment and control groups (P<0.05) for a given day. 
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Fig. 4.3. Growth rate of the dominant follicle for the first 5 days post-treatment (Fig. A to 
C) and the average growth rate (Fig. D to F) for T1 (Fig A and D), T3 (Fig. B and E) and 
T6 (Fig. C and F) treatment groups compared to the control (C) group within the same 
period. The number at each day after treatment represents the difference between the 
diameter of dominant follicle on that day from that of the previous day. For T1 and T3 
groups, control group (C* n=12) included all untreated control animals (n=6) combined 
with those from T6 group (before initiation of treatment). P-values for treatment (T), day 
(D) and treatment*time interaction (T*D) are indicated on Fig A to C and P-value 
between treatment and control group is indicated on Fig D to F. 
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4.4.2.4 Follicle numbers 
 There were no differences among treatment groups and the control group in the 
number of follicles in different size categories (4-5, 6-8, and ≥ 9 mm) in the first, second 
or ovulatory waves (Fig 4.4). 
 
Fig 4.4. Mean number of follicles in different diameter groups (4-5, 6-8, and ≥ 9 mm) 
during first, second, and ovulatory waves. Treatment groups T1, T3 and T6 were given 
200 mg of unconjugated testosterone twice (at 12 hr intervals) on Days 1, 3 or 6 of the 
first follicular wave, respectively while control (C) group was given placebo (canola oil) 
treatment. Data were centralized to the mean day of wave emergence (Day 0) for Wave 1 
(left graphs), Wave 2 (middle graphs) and Ovulatory Wave (right graphs). P-values for 
treatment (T), day (D) and treatment*time interaction (T*D) are indicated on the graphs. 
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4.4.2.5 Corpus luteum diameter and progesterone concentration 
  No differences were found among treatment groups (data not shown) in CL 
diameter profiles, therefore, the data from T1, T3 and T6 groups were combined. When 
combined treatment group was compared to the control group, there was no difference in 
CL diameter during the first and second portions  (P= 0.49 and P=0.58, respectively), but 
the CL regressed more rapidly (P<0.05) in testosterone treated heifers after Day 15 of 
cycle (Fig 4.5A). However, the first day of CL regression did not differ among treatment 
groups (Table 4.1, P=0.35) or between the testosterone treatment (combined treatment  
group) and the control group (Table 4.2, P=0.14). Testosterone treatment did not affect 
plasma progesterone concentrations between Days 11-17 of cycle (Fig. 4.5B).  
 
5.4.2.6 Gonadotrophin Hormone Analysis  
Heifers treated with testosterone (combined treatment group) had a decrease in 
LH concentrations post-treatment compared to the control group (Fig. 6A, P=0.01). Mean 
plasma LH concentrations following treatment were lower than those before testosterone 
treatment (P=0.04), but did not differ from the control group (Fig 6E). Treatment on 
Days 1 and 3 suppressed mean plasma LH concentrations significantly (Fig. 6 B and 6C; 
P=0.03 and P=0.05 respectively), while treatment on Day 6 only numerically reduced 
plasma LH concentrations (Fig. 6D, P= 0.11). When intensive bleeding data were 
examined, LH concentrations for the combined treatment group were not affected for the 
first 24 hr after treatment (Fig.6 F), but declined significantly (P<0.03) at 36 and 48 h 
after treatment (Fig. 6G). 
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Fig. 4.5. Comparison of corpus luteum diameter (mean ± SEM) profile (Fig. A) and 
plasma progesterone concentrations (Fig. B) between the combined testosterone 
treatment groups (T) and the control group (C). Corpus luteum diameter data (Fig. A) 
were divided into three phases for statistical analysis (Days 1 to 6, 7 to 12, and 13 to 18 
from ovulation) and progesterone data are presented for Days 11 to 17 (Fig. B). P-values 
for treatment (T), day (D) and treatment*time interaction (T*D) are indicated on the 
graphs 
 
FSH concentration did not differ among treatment groups versus the control group 
or between the combined treatment group and the control group (Fig. 7). In addition, 
mean FSH concentrations before or after treatment did not differ among groups (Fig. 7E, 
P=0.12). 
 
4.4.2.7 Comparison of synchrony of wave emergence among treatment groups 
 The interval from treatment to emergence of the next follicular wave was highly 
variable among treatment groups compare to controls (Fig 8A, P=0.02). The deviation of 
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day of wave emergence from the group mean was greater in T1 and T6 treatment groups 
compared to control group (Fig. 8 B, P= 0.01 
 
4.4.2. Analysis of data based on first wave interwave interval 
The first wave IWI (interval between the day of wave emergence of Wave 1 and 
2) for the control group was 8.7±0.42 (Table 4.1, n=6, range 5 to 8 days). When data  
from testosterone treated heifers were analyzed irrespective of the day of the wave on 
which treatment was given (i.e. all testosterone treated animal together; n=17), the first 
wave interwave intervals showed two patterns (Fig. 9A): animals in which interwave 
interval was similar to control, i.e., ≤11 days (normal group, TN) or ≥12 days (delayed 
group, TD). The number of treated heifers in TN group was 9 (T1, n=3; T3, n=3; T6, 
n=3) while the number of heifers in TD was 8 (T1, n=3; T3, n=3; T6, n=2). The interval 
between day of treatment and emergence of the next wave was longer for TD group 
(11.6±0.88 day, P= < 0.001) compared to TN (6.0±0.71 day) group. This difference in 
interval to wave emergency was associated with difference in timing  of the FSH surge 
between TN and C verses the TD ( Fig 4.9B) group. Plasma progesterone and 
testosterone concentrations and the diameter of first wave dominant follicle did not differ 
between the TN and TD groups (P= 0.45, P= 0.14, and P=0.11 respectively). During 
treatment, plasma FSH (Fig 4.9C) and LH (Fig 4. 9D) concentrations in TD group were 
lower (P=0.04 and P=0.02) than in TN group. 
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Fig. 4.6. Mean (±SEM) plasma LH concentrations after treatment with 200 mg 
unconjugated testosterone twice at 12 hr intervals: Combined testosterone treatment 
group (Fig. A, E, F, G), T1 (Fig. B), T3 (Fig. C), and T6 (Fig. D) groups compared to 
controls (C). Fig E compares the mean concentration of plasma LH before (Day -1 and 0; 
black box) and after treatment (Days 1-5; white box) between control and combined 
treatment group. Fig F and G illustrate the change in plasma LH concentrations from 0 to 
24 and -12 to 72 hr, respectively after treatment. P-values for treatment (T), day (D) and 
treatment*time interaction (T*D) are indicated on the graphs and different letters on top 
of bars in Fig. E indicate statistical differences (P < 0.05). Day 0 = day of treatment.  
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Fig.4.7 Mean (±SEM) plasma FSH concentrations after treatment with 200 mg 
unconjugated testosterone twice at 12 hr intervals: Combined testosterone treatment 
group (Fig. A, E, F, G), T1 (Fig. B), T3 (Fig. C), and T6 (Fig. D) groups compared to 
controls (C). Fig E compares the mean concentration of plasma FSH before (Day -1 and 
0; black box) and after treatment (Days 1-5; white box) between control and combined 
treatment groups. Fig F and G illustrate the change in plasma FSH concentrations from 0 
to 24 and -12 to 72 hr after treatment, respectively. P-values for treatment (T), day (D) 
and treatment*time interaction (T*D) are indicated on the graphs. Day 0 = day of 
treatment   
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Fig.4.8 Distribution of day of next wave emergence after treatment (Fig A) and deviation 
among animals from the mean day of wave emergence (Fig. B) among animals treated 
with testosterone on Days 1 (T1), 3 (T3), 6 (T6) after ovulation and control (C). 
Individual symbols in Fig A represent each animal; symbols with horizontal bar indicate 
group mean±SEM. For Fig B, difference between group mean and data point of each 
animals was defined as “deviation from mean” and analyzed by one-way analysis of 
variance. Different alphabets on top of bars in Fig. B indicate statistical differences 
(P<0.05). Day 0 = day of treatment. 
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Fig.4.9 Treated heifers were distributed into two groups based on the second wave 
emergence (before 12 days; TN, or after 12 days; TD). A) Day of second wave 
emergence in TN, TD and control. B) The surge of FSH of TD, TN and C (the FSH 
concentration was measured 4 days before wave emergence and 1 day after). C) 
differences in FSH percentage between TD and TN after testosterone treatment for 5 
days. D) The different in LH percentage between TD and TN after testosterone 
treatment for 5 days after treatment. 
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4.5 Discussion 
Our hypothesis that the administration of testosterone will shorten the life-span of 
the extant dominant follicle resulting in early emergence of a new follicular wave was not 
supported. Dominant follicle development after testosterone treatment differed depending 
on stage of follicle development at the time of treatment. Treatment on Days 1 or 3 
resulted in reduced the plasma LH concentrations and a decreased growth rate of the 
dominant follicle. However, treatment on Day 6 did not affect plasma LH concentration  
but delayed follicular regression. In all treatment groups emergence of the next follicular 
wave was delayed, resulting in a tendency for more 2-wave cycles than in control heifers.  
 In Experiment 1 (pilot study), we tested two formulations of testosterone to 
determine which formulation would sustain elevated testosterone levels and for how long 
a period of time. Basal levels of circulating testosterone in cattle are <1 ng/mL (Nix et al., 
1998; Wise et al., 1982). Results from our pilot study showed a marked difference in 
plasma testosterone levels following one or two im treatments with unconjugated (free) 
testosterone and testosterone enathnate (Fig.4.1) which was consistent with previous 
reports (Nix et al., 1998; Silvia et al., 1989). Plasma levels of testosterone increased 
slowly after treatment with testosterone enathnate while testosterone concentration 
increased more than 10 fold within 1 hr after injection of free testosterone.. Testosterone 
enathnate contains an ester group that improves the solubility of testosterone in oil 
(Encyclopedia, 2011). As a result, testosterone enathnate is released slowly over a 
prolonged period of time from its injection site into the blood stream. On the contrary, 
unconjugated testosterone would enter the blood stream very quickly. Based on our 
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knowledge of estradiol formulations (Martinez, 2005; Mapletoft, 1999), we wanted to 
achieve high circulating concentrations of testosterone for a 24 hr period to cause local 
(Billig et al., 1993; Jia et al., 1985) and systemic effects (Thompson et al., 1984), 
followed by a sharp decline in circulating plasma concentration to remove these effects. 
The pilot study indicated that the unconjugated testosterone formulation would achieve 
the desired levels of plasma testosterone for hypothesis testing. Our results indicated that 
12 h after the testosterone injection (Fig. 4.1C,D), plasma levels dropped to 50% of the 
peak levels, a second injection was administered at that time to maintain elevated levels 
of testosterone for at least for first 24 hr. 
Depletion half-life of testosterone was estimated to be 3.2 days and testosterone 
concentrations were maintained above 14 ng/mL (range: 28.7-14.5 ng/ mL) for 36 hr 
(Chapter 3). By 48 hr after first treatment, plasma concentration of testosterone dropped 
to 6.1 ± 0.17 ng/mL. Therefore, we were confident that our testosterone preparation and 
treatment regimen were suitable to cause the physiological effects on follicular and luteal 
dynamics, and systemic hormone concentrations of other reproductive hormones. 
Results document that increasing plasma testosterone concentrations resulted in 
several changes in follicular wave dynamics. When the testosterone treatment was given 
during the growing phase of the dominant follicle, before or at selection (Day 1or 3 
groups, respectively), it suppressed the growth of dominant follicle. Slower growth rates 
of the dominant follicle were associated with a concurrent reduction in plasma LH 
concentrations. LH secretion is required for growth of the dominant follicle, especially 
after selection when it becomes more LH dependent (Lucy, 2007). Reduction in mean LH 
concentrations and LH pulse frequency are considered crucial factors that decide the fate 
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of dominant follicle (Savio et al., 1993). The effect of testosterone on circulating LH 
concentrations in this study is in agreement with results of a previous study in which of 
the administration of 200 mg of testosterone per day for 4 days resulted in a reduction in 
circulating LH concentrations and regression of the preovulatory follicle (Rajamahendran 
and Manikkam, 1994). Unexpectedly, testosterone treatment during the early static phase 
(Day 6) resulted in slower regression of the dominant follicle. Although the difference in 
LH concentrations between the treatment and control groups following treatment on Day 
6 was not statistically significant, LH concentrations were numerically lower and 
followed the same trend as observed following treatment during the growing phase of the 
dominant follicle. The inability to detect statistical differences in LH concentrations 
following testosterone treatment on Day 6 may relate to changes in circulating 
progesterone concentrations. By Day 6 of the cycle, the corpus luteum is fully functional 
and producing large amounts of progesterone (Adams et al., 1992b; Rhodes et al., 1995) 
which suppresses LH release, making it difficult to detect a suppressive effect of 
testosterone treatment.  
The effect of testosterone on LH concentration may be a result of a direct effect 
on the pituitary gland (Yasin et al., 1996) or indirectly through modulation of estradiol 
production (Abbot et al., 1988). A study in ovariectomized cows and mares revealed a 
17% and 34% (respectively) reduction in LH release after GnRH challenge in 
testosterone treatment animals (Thompson et al., 1984) indicating that observed reduction 
in LH levels in our study may be partially due to extra-ovarian effects of testosterone. In 
ruminants, LH concentrations in the circulation reflect changes in LH beta subunit 
mRNAs expression in adenohypohysis (Aspden et al., 2003; Fetherston and Boime, 1982; 
	   65	  
Wise et al., 1985). Studies in a rodent model also indicate that androgen treatments 
modulate LH beta subunit mRNA expression in the pituitary gland, and GnRH mediated 
LH release and synthesis of mRNA β-subunit (Keri et al., 1994b; Krey et al., 1982; Yasin 
et al., 1996). These effects may be mediated by androgen receptor interaction with 
steroidogenic factor-1 (Curtin et al., 2001; Jorgensen and Nilson, 2001). One study in 
female rats showed that a high dose of testosterone suppressed LH secretion and LH ß 
mRNA response to GnRH (Yasin et al., 1996). These studies imply that testosterone can 
have a direct negative effect on LH secretion through modulate the responsiveness of 
pituitary gland to GnRH release . 
The second possible pathway for the observed testosterone-mediated LH 
suppression is through altering the follicular products, especially estradiol production. 
Testosterone is one of the known substrates that can be aromatized to estradiol (Walters 
et al., 2008), so the high amounts of testosterone that were injected in animals may 
increase the level of estradiol by aromatase activity of the granulosa cells of growing or 
early static dominant follicles. To support this notion, testosterone treatment of granulosa 
cells in vitro, has been shown to stimulate aromatase activity (Wu et al., 2011). 
Consequently, estradiol concentrations may have increased in the blood leading to 
suppression of the dominant follicle growth (Bo et al., 2000) by reducing the frequency 
and the amplitude of LH pulses (Wolfe et al., 1992). Unfortunately, plasma estradiol 
concentrations were not measured in this study. It is interesting to note that the growing 
dominant follicle did not undergo complete regression following testosterone treatment 
and it resumed growth. Although a suppressive effect of testosterone treatment on Days 1 
or 3 was observed for 5 days, its magnitude may not be sufficient to cause complete 
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regression of the dominant follicle or testosterone treatment may have a negative short 
term effect on LH concentration. 
The emergence of the next wave was delayed in half of the testosterone-treated 
heifers (Fig. 4.9A) and there tended to be more 2-waves cycles in testosterone-treated 
heifers compared to control group. This may be a result of the effect of converted 
estradiol that can suppress the FSH surge leading to a delay in emergence of the next 
follicular wave (Bo et al., 2000). In another study, treatment with estradiol valerate on 
Day 3 or 6 of the first follicular wave resulted in a delay in emergence of the next wave, 
presumably by delaying the FSH surge (Bo et al., 1993).  
It is noteworthy that number of follicles in the wave did not differ among 
treatment groups. Compared to very synchronous wave emergence following estradiol 
treatment (Bo et al., 1993), the interval between testosterone treatment and emergence of 
the next wave was highly variable, suggesting that testosterone is unlikely to be useful for 
the synchronization of follicle wave emergence. It has been shown that follicle wave 
emergence is stimulated by a surge of FSH (Adams et al., 1992a; Kulick et al., 1999). In 
the present study, the group of heifers in which emergence of the next wave was delayed, 
the FSH surge was also delayed compared to the control group or those animals in which 
wave emergence was not delayed (Fig4.9 B,C). These effects are likely due to a direct 
negative feedback of estradiol on the pituitary gland (Adams et al., 1992a; Roche et al., 
1998). The effect of testosterone treatment on timing of next wave emergence in our 
study was consistent with report in which 5 mg of estradiol valerate in heifers resulted in  
delayed and more variable intervals to emergence of a new follicular (Bo et al., 1993). In 
our study, we speculate that the delay of the FSH surge and emergence of the next wave 
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may either be due to direct suppressive effects of estradiol or testosterone on 
hypothalamic-pituitary axis or the ability of testosterone to keep the dominant follicle  
functional for a prolonged period of time. Although follicular growth was initially 
suppressed due to a decline in LH levels, testosterone treatment may have increased the 
expression of intrafollicular factors such as estradiol or IGF-1 that kept the dominant 
follicle functional (Quirk et al., 2004). This notion is supported by the finding that the 
early static phase dominant follicle (T6 group) maintained its diameter for a longer 
period. This ability of testosterone treatment to prolong the dominant follicle growth 
profile may be the result of increasing levels of estradiol in the follicular fluid through an 
increase in the availability of testosterone in blood and an increase in the expression of 
aromatase activity in granulosa cells (Wu et al., 2011). Consequently, the follicle that 
remains estradiol active has the ability to continue growing (Ireland and Roche, 1983). In 
addition, high estradiol concentration has been shown to increase the secretion of IGF-I 
by porcine granulosa cell (Hsu and Hammond, 1987). IGF-I has also been shown to 
suppress follicle apoptosis (Chun et al., 1994) and the increasing IGF-I expression has 
been shown to enhance the responsiveness of follicular cells to FSH and LH resulting in 
additional growth and steroidogenesis in dominant follicles (Bao and Garverick, 1998). It 
may be speculated that testosterone treatment provided a high level of testosterone that 
was converted to estradiol in the dominant follicle leading to the suppression of the FSH 
surge and delayed follicle wave emergence.  
It is interesting to note that testosterone concentrations increase before CL 
regression in the cow (Peterson et al., 1978; Wise et al., 1982), goat (Homeida and 
Cooke, 1984) and sheep (Herriman et al., 1979), which suggests that testosterone might 
	   68	  
play an important role in luteolysis (Homeida and Khalafalla, 1990; Tropea et al., 2010). 
In our study, CL diameter in the combined treatment group regressed more rapidly than 
in the control group (Table 4.2), however, we could not document any changes in 
circulating levels of progesterone during this period (11-17 day from ovulation). Our 
results are consistent with the findings of another study (Silvia et al., 1989) in which no 
difference in progesterone concentration was found between heifers treated with 
androgen (testosterone and dihydrotestosterone) versus untreated control animals. In any 
case, the observed luteal effects appear to be very subtle. It is noteworthy that 
testosterone concentrations would have returned to normal by the time of luteal 
regression and any observed effects would be due to direct or indirect uterine influences 
because of elevated testosterone during first 6 days of the luteal development.  
In summary, testosterone treatment during the pre-selection and selection phases 
of the growing dominant follicle suppressed its growth rate, which was associated with a 
reduction in circulating LH concentrations. Treatment during the early static phase of the 
dominant follicle delayed the regression phase. Overall, extant and subsequent follicular 
wave intervals were longer and testosterone treated animals tended to have more 2-wave 
cycles than controls. In 8 out of 17 heifers in testosterone treatment groups, emergence of 
the next wave was delayed due to a delay in the FSH surge. Testosterone treatment failed 
to synchronize the emergence of next follicular wave, alter the number of follicles in 
different size categories, and had minimal effect on luteal function. In conclusion, after 
exogenous administration of testosterone, dominant follicles grew more slowly, but 
contrary to our hypothesis, treatment did not shorten the life-span of the extant dominant 
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follicle and did not result in early synchronous emergence of a new follicular wave. 
Rather, emergence of the next wave was delayed in some but not all animals.  
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5.0 GENERAL DISCUSSION, CONCLUSIONS AND FUTURE STUDIES 
5.1 General Discussion 
 Reproductive efficiency of farm animals is an important consideration for 
increasing the productivity of animals for economic benefits and food security. For this 
reason, many reproductive techniques have been developed and applied in farm animals 
to increase fertility, to get more offspring from animals with higher genetic value or to 
simply manage the breeding period. Follicular wave synchronization is one of these 
techniques that helps to improve the efficiency of artificial insemination and embryo 
transfer. Many drugs such as estradiol, progesterone, GnRH or LH or physical removal of 
the dominant follicle (i.e., follicular ablation) have been used for this purpose. Among 
these hormones, estradiol is most efficacious and practical to use; however, recent bans 
on use of estrogens in farm animals by the European Union have limited its availability in 
many countries. In this thesis, we investigated whether testosterone could be used as an 
alternative to estradiol for follicular wave synchronization. 
In this section, the results of two studies (Chapters 3 and 4) are summarized to 
show the effects of exogenous testosterone treatment on the ovarian function and 
hormone profiles in beef cattle. These results would be connected with available 
information related to this subject. To the best of our knowledge, this is the first study in 
cattle that investigated the effect of testosterone on the growth pattern of dominant 
follicle and corpus luteum during different phases of development, examined changes in 
the numbers of small follicles and emergence of next follicular wave, and correlated 
ovarian changes with systemic concentrations of hormones such as FSH, LH and 
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progesterone and testosterone. For this reason, we will use other species for comparison 
with our results. 
Testosterone is a steroid hormone that has been shown to play a crucial role in 
growth and reproductive performance. As an anabolic hormone, testosterone is used 
widely as growth promotant in farm animals (Lone, 1997). During follicular 
differentiation, testosterone acts as a substrate for estradiol and therefore plays an indirect 
but essential role in regulation of follicular development (Drummond, 2006). 
Testosterone has been shown to exert a negative effect on plasma concentrations of 
gonadotrophin hormones (LH, FSH) in males and females (Huang et al., 2001; Thompson 
et al., 1987). In cattle, testosterone has been used to androgenize cows for estrus detection 
(Nix et al., 1998). Furthermore, testosterone was used in pigs to increase the ovulation 
rate (Cardenas and Pope, 1994; Cardenas and Pope, 1997).  
It was expected that an injected overdose of testosterone would convert to 
estradiol resulting in increased estradiol concentration in the blood. High estradiol would 
a exert negative feedback on gonadotrophin hormones (FSH, LH) leading to regression of 
the existing dominant follicle. In addition, published results indicated that testosterone 
may have direct negative effects on granulosa cells (Hillier and Ross, 1979). Based on 
these effects, we predicted that exogenous testosterone treatment would decrease the life-
span of extant dominant follicle by direct systemic effects and/or indirect ovarian effects 
and therefore the suppressive effect of dominant follicle on FSH through estradiol would 
be removed leading to early emergence of next follicular wave. 
 At the beginning of this project, we needed to select a testosterone preparation 
and the dose that would be most likely to cause physiological effects. Based on previous 
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studies that used estradiol for follicular wave synchronization (Martinez et al., 2005, 
Colazo et al., 2002, Mapletoft 1999), we predicted that a testosterone preparation that 
results in sharp increase in plasma testosterone concentration followed by a decline over 
approximately 36 hr would be most suitable. This pattern of elevation in testosterone 
concentration was designed to exert high testosterone level for a specific period that may 
enough to suppress the dominant follicle growth and yet disappear rapidly enough to 
permit an FSH surge and allow emergence of a new wave. In the pilot study (Chapter 4), 
we tested testosterone enanthate (conjugated esterified preparation) and unconjugated 
testosterone (free-form). compared to unconjugated testosterone. Two injections of 
testosterone enanthate at 24 hr intervals resulted in a very small increase and very slow 
decline in plasma concentration of testosterone (Fig 4.1). Therefore, we selected 
unconjugated testosterone for further studies,however, by the end of first 24 hr period 
(i.e., at the time of second injection), plasma testosterone had decreased markedly. 
Consequently, we opted to decrease the interval between two injections to 12 hours for 
the final study. The results of pharmacokinetic study (Chapter4) indicated that plasma 
testosterone concentration increased quickly (2 hr) after injection of unconjugated 
testosterone and testosterone concentrations were maintained above 14 ng/mL (28.7-14.5 
ng/ mL ) for 36 hours (after two injections). Depletion half-life of testosterone was 3.2 
days and plasma concentrations returned to baseline within 2 weeks. These levels 
compare very well those obtained in another study ( Rajamahendran and,Manikkam, 
1994) where daily injections of 200_mg of testosterone _in oil ( the average of the 
maximum testosterone concentration after first injection was 16 ng /mL) over 4 day 
period caused atresia of the preovulatory follicle. We were confident that the type of 
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testosterone (unconjugated free form), dose of testosterone (200 mg) and treatment 
design (two im injections at 12 hr intervals) were optimal for detecting ovarian and 
hormonal effects. 
Exogenous testosterone treatments were initiated when the dominant follicle was 
in the preselection growth phase (Day 1 of wave), at the time of selection (Day 3) or post-
selection at beginning of the static phase (Day 6) of the first follicular wave (Chapter 4). 
Testosterone treatment on Days 1 and 3 decreased the growth rate of dominant follicle for 
next 4 to 5 days while treatment on Day 6 caused the dominant follicle to regress more 
slowly than controls (Fig 4.3). Testosterone treatment did not cause the complete demise 
of the dominant follicles at any stage and the next wave emergence did not emerge early 
or synchronously. Contrary to our hypothesis, the next wave emergence in all treatment 
groups was delayed (Table 4.1, 4.2).  
Underlying causes of altered follicular function appear to be the effects of 
exogenous testosterone treatment on plasma LH concentrations. Compared to controls, 
LH concentrations were reduced for 5 days post-treatment (Fig 4.6) on Day 1 and Day 3 
of the follicular wave. It is known that LH is required for dominant follicle growth after 
selection (Lucy, 2007). Observed LH reduction is consistent with results of studies that 
used testosterone treatment in female rats (Hassani et al., 1978 ; Yasin et al., 1996) and 
ovariectomized cows and mares (Thompson et al., 1984). In these studies testosterone 
had an estradiol-independent direct effect on gonadotrophin secretion. It has been 
observed that testosterone negatively affects the expression of LH β subunit mRNA in the 
pituitary gland that consequently reduces the amount of LH release (Aspden et al., 2003; 
Wise et al., 1985). In addition, enhanced conversion of testosterone to estradiol 
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conversion could modulate the LH secretion (Abbot et al., 1988). It is not yet clear what 
caused LH suppression, that is, whether it occurred due to a direct action of testosterone 
on the hypothalamic-pituitary axis, or conversion of testosterone to estradiol or both. 
Although the experiment was not designed to address this question directly, it may be 
partly answered by plasma estradiol analysis. Unfortunately, this assay was not available 
for the present investigation due to technical problems. On Day 6 of follicular wave, the 
situation was different; our results show that the treatment at this time had no effect on 
LH concentration or the diameter of the dominant follicle. It may the interaction between 
the stage of dominant follicle development (fully growing follicle) and hormonal meliu at 
the time of treatment that played role at this stage  causing a different response from other 
groups. 
It has been shown that the effect of testosterone on gonadotrophin hormones 
requires up to 24 hr before GnRH is suppressed in gonadectomized animals (Gharib et 
al., 1986; Yasin et al., 1996). In our study, LH concentrations were reduced by 24 hr in 
testosterone treated animals compared to controls (Fig. 4.6 G), which implies that this 
effect may be due to a direct action of testosterone on the hypothalamus or pituitary 
gland. In general, the magnitude of the LH suppression may not be sufficient or the 
period of low LH was not long enough to cause complete regression of the extant 
dominant follicle. Although the growth of pre-selection (Day 1) and recently selected 
(Day 3) dominant follicles was reduced, these follicles kept growing and remained active 
for a prolonged period of time, thereby delaying the emergence of next wave. Based on 
the results from Chapter 4 (Fig 4.1), plasma testosterone concentration in all treatment 
groups remained elevated for several days after treatment and returned to baseline levels 
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only after 2 weeks. The availability of high concentrations of testosterone may have 
induced stimulatory effect on aromatase activity (Wu et al., 2011) resulting in increased 
level of estradiol production by granulosa cells. The high level of estradiol could have 
modulated the effects of testosterone on LH secretion (Abbot et al., 1988; Bo et al., 
2000). It is interesting to note that when high doses of long-acting estradiol esters (e.g. 
estradiol valerate) were injected (Martinez et al 2005), the FSH surge was delayed and 
occurred at variable times after treatment resulting in delayed follicle wave	  emergence	  and	   high	   variability. This situation is analogous to what we observed in our study. 
Regardless the underlying mechanism; dominance was maintained for a longer period of 
time leading to delay in the next wave emergence in all treatment groups.  
It has been observed that estradiol exerts suppression of FSH release (Bo et al., 
2000) and when the estradiol effect was removed, the synchrony of FSH release resulted 
in the synchronized emergence of a new follicular wave (Adams et al., 1992a; Bo et al., 
1995a). In contrast to estradiol, we failed to demonstrate any immediate decrease in 
plasma FSH concentrations after the testosterone treatments in our study but the delay in 
wave emergence in treated heifers was associated with delay in FSH surge.	   In other 
words, we cannot identify the mechanism by which the FSH surge was delayed; whether 
it was by converted estradiol or by direct effect of testosterone is not clear. Another 
notable observation was that different heifers within each treatment group responded 
differently. Overall, based on interval to emergence of the next wave emergence, heifers 
were divided into two groups. In one group, time of next wave emergence was not 
different from that observed for control group (TN), while in the second group there was 
a clear delay in next wave emergence (TD), although these animals were given same dose 
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of testosterone as to the first group. The reason of this variation among heifers is not 
understandable and we could not find an explanation for this biphasic response. 
Testosterone treatment did not have an effect on the number of > 4 mm follicles 
that were recruited into different follicular waves (second and ovulatory waves), or the 
plasma progesterone concentration during the same period, i.e., 11-17 post ovulation. 
Therefore, it appears that observed ovarian and endocrine effects of testosterone were 
limited to a one week period post-treatment . On the other hand, the CL diameter of 
treatment group between Days 13-17 post-ovulation showed minor differences from the 
control group, length of the second wave was longer after treatment and testosterone-
treated heifers tended to have more 2-wave cycles. The last two effects are inter-related; 
treated heifers had more two-wave cycles and the length of second (anovulatory) wave in 
3-wave cycles is shorter than that the length of second (ovulatory) wave in 2-wave cycles 
(Jaiswal et al., 2009). 
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5.2 General conclusions  
Based on the research that was conducted for this thesis, we conclude the following 
points: 
• Two intramuscular injections of oil-based unconjugated testosterone (200 mg) at 12 
hr intervals can be used effectively to maintain plasma testosterone concentrations 
above 10.9 ng/mL for 36 hr from start of the treatment. Elimination half-life of 
this preparation of testosterone in the blood stream was 3.2 days and plasma 
concentrations returned to baseline within 2 weeks. 
• Testosterone treatment did not shorten the life-span of the extant dominant follicle 
or induce early emergence of next follicular wave; our proposed hypothesis was 
not supported. 
• Testosterone treatment given before or at the time of selection, suppressed plasma 
LH concentrations and dominant follicle growth rate, while treatment in the early 
static phase did not affect LH concentration, but led to slow regression of the DF 
• Testosterone treatment delayed emergence of the next wave irrespective of the day 
of treatment. Next wave emergence was not synchronous. 
• Heifers treated with testosterone tended to have more 2-wave cycles 
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5.3 Future studies   
 The studies reported in this thesis clearly documented the follicular and hormonal 
effects of testosterone but also raised many questions for future studies: 
• One limitation of this study is the lack of estradiol measurements in plasma. 
Attempts were made, however, estradiol concentrations could not be reliably 
measured due to lack of a sensitivity and specificity of existing estradiol 
radioimmunoassay. 
• There is need to identify the cause of eduction in plasma LH concentrations. This 
is important to understand the underlying mechanism of action of testosterone. 
• Perform a more elaborate pharmacokinetic study of testosterone in cattle that 
would report important information missing in our work especially the 
testosterone residues in tissues. 
• Repeat the study after increasing the dose of testosterone to test if greater 
suppressive effect on LH would cause complete demise of the dominant follicle. 
• Are multiple injections of testosterone needed to get effective and consistent 
results and can a single very high dose cause sufficient LH suppression?  
• Will lactating dairy/beef cows respond differently to testosterone compared to 
heifers in this study? 
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Appendix 1 
Statistical analysis model for single-point measurements  
 
1-Mixed model procedure using CRD (Complete randomize 
design )  
 
Data hayder ; 
Input ID TRT$ X; 
Cards; 
72 T1 24 
198 T1 40 
156 T1 24 
176 T1 18 
1 T1 45 
65 T1 21            
.                          . 
 .                          . 
 .                          . 
.                          . 
 .                          . 
; 
PROC UNIVARIATE DATA=Hayder NORMAL PLOT; 
VAR X; 
BY TRT; 
RUN; 
PROC MIXED DATA=hayder; 
CLASS TRT; 
MODEL X=TRT/DDFM=SATTERTH; 
RUN;  
 
If the model was significant, we tested the different among the treatments over the 
time by using LSD as following way: 
 
Data hayder ; 
Input ID TRT$ X; 
Cards; 
72 T1 24 
198 T1 40 
156 T1 24 
176 T1 18 
1 T1 45 
65 T1 21 
                             
                             
To	  test	  the	  normality	  of	  data	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; 
PROC MIXED DATA=hayder; 
CLASS TRT; 
MODEL X=TRT/DDFM=SATTERTH; 
Lsmeans TRT/pdiff; 
RUN;  	  
2-Mixed model procedure using t-test (comparing between 
tow combined treatment vs control groups) 
 
Data hayder ; 
Input TRT$ X; 
Cards; 
T 17 
T 13 
T 14 
T 9 
T 10 
T 9 
T 8 
T 14 
T 10 
T 13 
T 13 
T 9 
T 14 
T 10 
T 10 
T 18 
T 9 
T 14 
C 10 
C 9 
C 8 
C 9 
C 9 
C 7 
; 
proc ttest data=hayder h0=0; 
class trt; 
var x ; 
run; 
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Appendix 2 
Statistical analysis model for serial data 
 
1- Mixed model procedure (Repeated Measures)  
 
 
Options nocenter; 
Data hayder ; 
Input ID TRT$  Day X                 
Cards; 
72 T1 0 1.08 
72 T1 1 0.67 
72 T1 2 0.49 
72 T1 3 0.61 
72 T1 4 0.70 
72 T1 5 0.60 
72 T1 6 0.99 
198 T1 0 0.16 
198 T1 1 0.42 
198 T1 2 0.38 
                                           . 
.                                          . 
.                                         .  
                                           . 
.                                          . 
.                                          . 
.                                          . 
.                                          . 
                                           . 
.                                          . 
.                                          . 
.                                          . 
.                                          . 
                                           . 
.                                          . 
; 
proc sort data=hayder; 
by trt; 
run; 
Proc means n nminss min mean max std stderr data=hayder; 
Var X 
By TRT; 
Run; 
Title'AR'; 
X= Parameters (eg. 
FSH, Dominant follicle 
diameter) 
TRT= Treatments 
Day= Time of samples 
ID= Animals number  
   
This syntax gave us 
some parameters of  
our  data   such as 
mean , minimum or 
maximum value of 
treatments over the 
time  
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Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = AR r rcorr; 
Run; 
 
Title'AR(1)'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = AR(1) r rcorr; 
Run; 
Run; 
Title 'TOEP' ; 
 Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = TOEP r rcorr; 
Run; 
Title’ARH(1)’ ; 
 Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = ARH(1) r rcorr; 
Run; 
Title' TOEPH'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type= TOEPH r rcorr; 
Run; 
Title' CS'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = CS r rcorr; 
Run; 
Title' HF'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = HF r rcorr; 
Run; 
Title' simple'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
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model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = SIMPLE r rcorr; 
Run; 
 
Title' ANTE1'; 
Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = ANTE(1) r rcorr; 
run; 
 
To fined the best covariance strictures model, it was tested different types from it and the 
covariance stricture that had lowest  AIC and BIC (AIC= Akaike’s Information Criterion; 
BIC= Bayesian Information Criterion) was considered the best model to analyze the data. 
If the model was significant, we tested the different among the treatments over the time 
by using LSD as following way: 
 
Options nocenter; 
Data hayder ; 
Input ID TRT$  Day X                 
Cards; 
72 T1 0 1.08 
72 T1 1 0.67 
72 T1 2 0.49 
72 T1 3 0.61 
72 T1 4 0.70 
72 T1 5 0.60 
72 T1 6 0.99 
198 T1 0 0.16 
198 T1 1 0.42 
198 T1 2 0.38 
                                           . 
.                                          . 
.                                         .  
                                           . 
.                                          . 
.                                          . 
.                                          . 
.                                          . 
                                           . 
.                                          . 
.                                          . 
.                                          . 
.                                          . 
                                           . 
.                                          . 
; 
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Title 'TOEP' ; 
 Proc mixed data=hayder covtest cl; 
Class ID  TRT DAY; 
model X=TRT DAY TRT*DAY/DDFM=KR htype=3; 
Repeated DAY/subject=ID type = TOEP r rcorr; 
lsmeans trt|day/pdiff ; ………………………………………..   
Run; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This syntax used to 
find the different 
among treatments 
over the time of the 
study for specific 
parameters  
